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 ABBREVIATIONS 
 
A   adenine 
ACF   aberrant crypt foci 
AFAP   attenuated familial adenomatous polyposis 
AI   allelic imbalance 
AMPK   AMP-activated protein kinase 
APC   adenoamtous polyposis coli 
AURKA  aurora kinase A 
bp   base pair 
BAX   BCL2-associated X-protein 
BCL2/Bcl-2  B-cell lymphoma 2 gene/protein 
BLM   bloom syndrome gene     
BMPR1A  bone morphogenetic protein receptor-1A 
BRAF   v-raf murine sarcoma viral oncogene homolog B1 
BRCA1/2  breast and ovarian cancer gene-1/2 
BRG1(SMARCA4) SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
C   cytosine 
CCND1  cyclin D1 
CCNT2  cyclin T2 
CD95(Fas)  tumor necrosis factor receptor superfamily, member 6 
CDK9   cyclin-dependent kinase-9 
CDKN2B  cyclin-dependent kinase inhibitor 2B 
cDNA   complementary deoxyribonucleic acid 
CGH   comparative genomic hybridization 
CHRPE  congenital hypertrophy of the retinal pigment 
CIN   chromosomal instability 
cM   centiMorgan 
C-MYC  myelocytomatosis viral oncogene homolog 
CRC   colorectal cancer 
cRNA   comprementary ribonucleic acid 
CTNNB1  β-catenin 
DCC   deleted in colorectal cancer 
dCTP   deoxycytocine triphosphate  
DNA   deoxyribonucleic acid 
DPC4   deleted in pancreatic cancer-4 
dUTP   deoxyuracil triphosphate 
EGFR   epidermal growth factor receptor 
EPHB2/EphB2 ephrin type-B receptor-2 gene/protein 
EST   expressed sequence tag   
EXO1   exonuclease-1 
FAP   familial adenomatosis polyposis 
G   guanine 
GDP   guanosine 5’diphospate 
GSK-3β  glycogen synthase kinase-3β 
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GTP   guanosin 5’triphosphate 
HFE   hemochromatosis 
HH   hedgehog signaling 
HIF1α   hypoxia-inducible factor α  
HNPCC  hereditary non-poyposis colorectal cancer 
H-RAS   Harvey rat sarcoma viral oncogene homolog 
IDL   insertion-deletion loop 
IGFII   insulin-like growth factor-2 
IGFRII  insulin-like growth factor receptor-2 
JP   juvenile polyposis 
KRAS   Kirsten rat sarcoma viral oncogene homolog 
LKB1   serine/threonine kinase defective in PJS 
LOH   loss of heterozygosity 
LOI   loss of imprinting 
MAP   mitogen activated protein 
MBD4   methyl-CpG binding domain protein 4 
MGMT  o6-methylguanine-DNA methyltransferase  
MLH1/3  human mutL homolog-1/3 
MMR   mismatch repair 
MSH2-5  human mutS homolog-2-5 
MSI   microsatellite instability 
MSI-H   high microsatellite instability 
MSI-L   low microsatellite instability 
MSS   microsatellite stable 
MTA1   metastasis associated-1 
MTS   Muir-Torre syndrome 
MYH   human mutY homolog 
p   short arm of a chromosome 
q   long arm of a chromosome 
SMAD2/4  human homologs of Drosophila melanogaster Mad gene-2/4 
smo   smoothened   
PCR   polymerase chain reaction   
PJS   Peutz-Jeghers syndrome 
PMS1/2  human postmeiotic segregation increased-1/2 
PTCH/ptc  patched gene/protein   
RB   retinoblastoma gene 
RNA   ribonucleic acid 
SNP   single nucleotide polymorphism 
SSCP   single strand conformation polymorphism 
STK11   serine/threonine kinase-11 
STK15   serine/threonine kinase-15 
T   thymidine 
TCF   T-cell factor 
TGFβ   transforming growth factor-β 
TGFβRI/II  transforming growth factor-β receptor type I/II 
TP53(p53)  tumor protein 53 
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TS   Turcot syndrome 
UV   ultraviolet 
VEGF   vascular endothelial growth factor 
VHL   Von Hippel-Lindau syndrome gene 
wnt   wingless signaling pathway 
WT   Wilm’s tumor 
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ABSTRACT 
 
 
Colorectal cancer (CRC) is the third most common cancer in the Western countries. 
Some genetic alterations behind the colorectal tumor progression are well known, such as 
loss of chromosomal regions 5q, 17p and 18q. Genomic instability plays a key role in 
cancer development and multiple mutations in several genes eventually lead to invasive 
cancer. Despite that our knowledge of cancer development has increased during the past 
decades, many of the genetic alterations underlying cancer remains to be clarified. Which 
of these alterations are the key players in the initial development of colorectal cancer is 
not entirely known. 
  
Much of our information about the molecular pathogenesis of cancer has arisen from 
studies on hereditary tumors. Lynch syndrome is a hereditary colorectal cancer 
syndrome, which accounts for 1-5% of all CRCs. The underlying gene defects causing 
Lynch syndrome are well characterized. The moderate and low penetrance genes 
predisposing to colorectal cancer largely remain to be characterized. Though the main 
relevance of hereditary cancer studies relates to increasing understanding on the 
mechanisms of cancer development, such studies also benefit the cancer families. 
Knowledge of the underlying molecular features can lead to more accurate diagnosis, 
better treatment and prevention of cancer. 
 
Approximately 15% of CRCs display a phenomenon called microsatellite instability 
(MSI). MSI tumors show several clinical and molecular features differing from 
microsatellite stable (MSS) tumors. This classification can be utilized in CRC 
diagnostics. A panel of five microsatellite markers known as the Bethesda panel has been 
proposed for screening for MSI. To test a hypothesis that the use of the mononucleotide 
marker BAT26 alone is feasible in screening for MLH1/MSH2 mutation positive cases, 
494 colorectal cancer patients were studied. BAT26 status was compared to results 
obtained using the Bethesda panel. BAT26 was able to detect all mutation positive 
individuals in this series. To study the proportion and significance of tumors belonging to 
a third subgroup, MSI-low (MSI-L), 90 BAT26 stable CRC samples were analyzed with 
the five Bethesda markers and 372 additional microsatellite markers. Several molecular 
and clinical features were scrutinized, to examine the previously proposed differences 
between MSI-L and MSS tumors. Convincing differences between putative MSI-L and 
MSS groups were not observed and the results suggest that MSS and MSI-L tumors have 
a common molecular background. 
 
To identify new chromosomal regions for low and moderate penetrance genes 
predisposing to CRC a genome-wide allelotyping was performed on 29 familial and 75 
sporadic CRCs. The study revealed differences in AI pattern between sporadic and 
familial cases, and several chromosomal loci that displayed more AI in familial tumors 
were identified. The most promising region was located in chromosome 20q which was 
amplified more often in familial tumors compared to sporadic ones. Chromosome 20q 
may harbor a novel CRC predisposing gene. 
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Serrated colorectal tumors are a fairly recently characterized entity among CRCs. They 
are morphologically different from conventional adenocarcinomas but whether they are 
biologically different as well has not been clear. To study the molecular background of 
serrated CRCs the gene expression profile of 8 serrated CRCs was compared to 29 
conventional adenocarcinomas using microarrays. Several differentially expressed genes 
were identified and the expression differences were validated in a larger dataset using 
immunohistochemistry. The results establish serrated CRCs as a distinct entity with 
unique molecular basis. 
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REVIEW OF THE LITERATURE 
 
 
1. GENES AND CANCER 
 
Cancer is a serious health problem in the Western countries. In Finland over 20 000 
people develop cancer every year and almost 10 000 people die of it. Since the first 
cancer statistics from 1950 the cancer incidence has continuously increased. The most 
common cancer types today are prostate-, breast-, and colorectal cancer which account 
for 43% of all cancers (Table 1) (Finnish Cancer Registry. Cancer Statistics at 
www.cancerregistry.fi last updated on 30 Aug 2004).  
 
 
Table 1. The most common cancer types in Finland in 2002 
Cancer type Number of cases (% of all cancers) 
Prostate 3930 (17%) 
Breast 3791 (16%) 
Colorectal 2236 (10%) 
Lung 1861 (8%) 
Skin 1518 (7%) 
 
 
Several environmental and lifestyle factors increase cancer risk. Exposure to UV-
radiation predisposes to skin cancer, and cigarette smoking is a known risk factor for lung 
cancer. Environmental factors do not, however, directly cause cancer since cancer is 
essentially a genetic disease. Malignant tumors arise when cells have acquired several 
mutations in DNA and are no longer able to control their own growth. Hanahan and 
Weinberg (2000) have proposed that six essential alterations in cell physiology are 
responsible for malignant growth (Figure 1). Tumor cells lose their capability to control 
cell cycle, differentiation, and programmed cell death. They are able to induce the 
formation of blood vessels and eventually invade to surrounding tissues and metastasize 
to other organs. 
 
Majority of cancers arise sporadically. In sporadic cancer mutations occur by chance in a 
single cell giving it a growth advantage. Cancer can, also, run in a family. In hereditary 
cancer a defective gene is present in every cell of its carrier. The age of onset in 
hereditary cancer is usually lower than in sporadic cancer and these families are 
characterized by accumulation of cancer in the family. Whether cancer is sporadic or 
hereditary, progression of a normal tissue to a cancer is characterized by accumulation of 
genetic alterations in the target tissue. The genes that underlie cancer are called 
oncogenes and tumor suppressor genes. 
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Figure 1. Alterations in cell physiology in cancer (modified from Hanahan & Weinberg, 
2000) 
 
 
1.1 Oncogenes 
 
Oncogenes are altered forms of normal cellular components called proto-oncogenes. In 
normal cells proto-oncogene expression results in increased cell birth or decreased cell 
death. Oncogenes are dominant at the cellular level. An inactivating mutation in either of 
the two alleles is sufficient to encourage increased proliferation. Oncogenes can be 
classified into different subgroups according to their function in cells. They can be e.g. 
growth factors, growth factor receptors, intracellular signaling proteins, cell cycle 
regulators and transcription factors. Proto-oncogenes become oncogenes through gain-of-
function mutations such as an activating point mutation, amplification or chromosomal 
translocation (Bishop, 1991). The first report of mutated proto-oncogene was presented 
by Reddy et al. in 1982. They observed a point mutation in HRAS codon 12 that 
converted glycine to valine in a bladder carcinoma cell line. Since then mutations have 
been found in over a hundred other proto-oncogenes (Futreal et al., 2004).     
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1.2 Tumor suppressor genes 
 
Tumor suppressor genes inhibit cell growth. Tumor suppressor genes act in a recessive 
manner, meaning that both alleles must be inactive before the effect of the gene product 
is lost. This was first suggested in 1971 when Knudson presented his famous two-hit 
hypothesis. He proposed that two genetic hits were sufficient to lead to retinoblastoma. 
Later, Cavenee et al. (1983) showed that when the first hit in retinoblastoma was a small 
change, the second one was usually a gross chromosomal alteration, such as a large 
deletion, resulting in loss of heterozygosity (LOH) in retinoblastoma (RB) locus. Most 
tumor suppressor genes act like RB. In hereditary cancer the first hit is the inherited 
mutation, while in sporadic cancer it is the acquired one. A somatic mutation, LOH or an 
epigenetic mechanism, such as promoter hypermethylation, then inactivates the other 
allele.  
 
1.2.1 Gatekeepers   
 
Gatekeepers are tumor suppressor genes that directly regulate tumor growth by inhibiting 
growth or by promoting death. The role of a gatekeeper gene varies in different tissues. 
Loss of function of a certain gene leads to a specific form of cancer so that inactivation of 
APC leads to colon cancer but not renal cancer, whereas mutations in VHL cause renal 
cancer but not colon cancer (Latif et al., 1993; Kinzler and Vogelstein, 1997). 
 
1.2.2 Caretakers 
 
Unlike gatekeepers, inactivation of a caretaker gene does not directly promote tumor 
growth. Inactivation of a caretaker leads to genetic instability that indirectly promotes 
tumor formation by causing an increased mutation rate in all genes in a cell, including 
oncogenes and tumor suppressor genes. Since several mutations are required for the full 
development of cancer, the inactivation of a caretaker can greatly increase the mutation 
rate in cells and thereby accelerate the tumor formation (Kinzler and Vogelstein, 1997). 
Similar to gatekeepers inactivation of a caretaker leads to tissue a specific tumor. For 
example mutations in DNA repair genes MLH1 and MSH2 underlie colorectal cancer, 
while BRCA1 and BRCA2 are mutated in breast cancer. 
 
1.2.3 Landscapers 
 
A third group of tumor suppressor genes, landscapers, are proposed to play a role in 
neoplastic transformation indirectly by creating an abnormal microenvironment. Patients 
affected with juvenile polyposis and ulcerative colitis develop hamartomatous polyps in 
which the proliferating cells are mostly stromal. The epithelial cells associated with 
abnormal stroma are more likely to become neoplastic due to an abnormal 
microenvironment (Kinzler and Vogelstein, 1998).      
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1.3 Epigenetic mechanisms 
 
Besides mutations, oncogenes and tumor suppressor genes can be activated/inactivated 
through epigenetic modifications. Epigenetic modifications are alterations in the genome 
that do not involve the DNA sequence itself (Verma and Srivastava, 2002). Epigenetic 
modifications are dynamic. In somatic cells they are passed on to the progeny of a cell 
through cell division, in germline, however, epigenetic modifications are reversible. The 
first indication that epigenetics play a role in cancer was the discovery of altered 
methylation in colorectal tumors (Feinberg and Vogelstein; 1983). In addition to aberrant 
DNA methylation, another epigenetic change associated with cancer is loss of imprinting 
(LOI). 
 
 
1.3.1 Methylation 
 
Methylation takes place at cytocine bases that are located 5' to a guanosine in a CpG 
dinucleotide. These dinucleotides are enriched in promoter regions of genes, and are 
called CpG islands (Larsen et al., 1992). In normal cells CpG islands are generally 
unmethylated. However, in cancer the hypermethylation of these promoter regions is a 
common epigenetic change, and is associated with the transcriptional silencing of tumor 
suppressor genes (Baylin and Herman, 2000). Genes that cause familial forms of cancer 
when mutated in the germ line are known to undergo methylation-associated silencing in 
sporadic cancer. Mismatch-repair gene MLH1 underlies hereditary colorectal cancer, and 
is methylated in sporadic microsatellite instable (MSI) colorectal cancers (Kane et al., 
1997; Herman et al., 1998). Additionally, there are a growing number of tumor 
suppressor genes that are silenced by promoter hypermethylation but seem not to be 
frequently mutated (Esteller et al. 2000).  
 
 
1.3.2 Loss of imprinting (LOI) 
 
Genetic imprinting is a form of epigenetic inheritance that distinguishes maternal and 
paternal alleles. Usually genes are expressed from both chromosomes, but imprinted 
genes show preferential expression of either a maternal or a paternal allele. Usually 
imprinting is mediated through a specific methylation pattern of an imprinted allele 
(Feinberg, 2002). Loss of imprinting leads to loss of the normal pattern of parental origin-
specific gene expression. In cancer it was first detected in an embryonal kidney cancer 
Wilm's tumor (WT). In normal kidney cells a growth-promoting gene insulin-like growth 
factor II (IGFII) is imprinted so that it is expressed preferentially from the paternal allele. 
LOI causes biallelic expression of IGFII increasing its concentration in a cell, and thus 
giving a growth advantage (Ogawa et al., 1993; Rainier et al., 1993). In addition to WT, 
several adult tumors including cervical, colorectal and liver tumors display LOI as well 
(Douc-Rasy et al., 1996; Takeda et al., 1996; Cui et al., 2003).  
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2. COLORECTAL CANCER  
 
Colorectal cancer (CRC) is the third most common cancer in Finland (Finnish Cancer 
Registry. Cancer Statistics at www.cancerregistry.fi last updated on 30 Aug 2004). It is 
common also in other Western world countries, as well as in some developing countries. 
Differences between races and ethnic groups, however, exist (Boyle and Leon, 2002). 
Several environmental factors may increase CRC risk. High body-mass index, increased 
meat consumption, and tobacco smoking are associated with higher CRC risk (Martinez 
et al., 1997; Willett et al., 1990; Giovannucci et al., 1996; Giovannucci 2001). A family 
history of CRC represents an independent risk factor. CRC in a family confers a 2-fold to 
6-fold increase in risk. The risk associated with family history varies greatly, and depends 
on the age of onset of CRC in family members, the number of affected relatives, and 
whether cancers have occurred in multiple generations (Goldgar et al., 1994; Dong and 
Hemminki, 2001; Risch 2001; Slattery et al., 2003). The proportion of CRCs considered 
to be familial depends on the definition. Approximately 5% of CRCs are caused by a 
highly penetrant inherited mutation in a cancer predisposing gene. If the low-penetrant 
susceptibility alleles are taken into account the proportion of familial CRC rises up to 20-
35%. The rest of CRCs are considered sporadic (Lichtenstein et al., 2000; de la Chapelle, 
2004). 
 
Hereditary CRC syndromes are divided into two groups: polyposis and non-polyposis 
syndromes. Polyposis syndromes are further divided into adenomatous and 
hamartomatous polyposis syndromes. 
 
 
2.1 Non-polyposis syndromes         
 
Lynch syndrome (Hereditary non-polyposis colorectal cancer) 
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is 
an autosomal dominant condition characterized by familial aggregation of early-onset, 
right-sided, synchronous and metachronous CRC. The incidence of Lynch syndrome is 
estimated to be 2-3% (Aaltonen et al., 1998; Salovaara et al., 2000). People affected with 
Lynch syndrome are in an increased risk for several other cancers besides CRC, such as 
endometrial, ovarian, small bowel, stomach, urinary tract, renal pelvis and brain (Watson 
and Lynch, 1993; Vasen et al., 1999). The lifetime risk of CRC of a person with Lynch 
syndrome is as great as 70-85%. Women have approximately 50% risk of endometrial 
cancer. The risk of other malignancies is below 20% (Watson and Lynch, 1993; Aarnio et 
al., 1995). Diagnosis of Lynch syndrome is based on the Amsterdam criteria. The 
Amsterdam criteria were created in 1991 to establish diagnostic guidelines for this 
syndrome, when the genetic basis was not yet clear. The criteria have since been revised 
to include extracolonic malignancies (Vasen et al., 1991; Vasen et al., 1999). The 
Amsterdam criteria are listed in Table 2.  
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Table 2. Amsterdam criteria for Lynch syndrome diagnosis 
  
• At least three affected relatives with Lynch syndrome associated cancer 
• One affected person is a first-degree relative of the other two affected persons 
• At least two successive generations should be affected 
• At least one cancer should be diagnosed before age 50 
• Familial adenomatous polyposis should be excluded 
• Pathological verification of tumors 
 
 
The genes underlying Lynch syndrome are DNA mismatch repair (MMR) genes. Four 
genes, MLH1, MSH2, MSH6, and PMS2 have been identified that, when mutated in 
germline cause susceptibility to Lynch syndrome (Fishel et al., 1993; Leach et al., 1993; 
Bronner et al., 1994; Nicolaides et al., 1994; Papadopoulos et al., 1994; Miyaki et al., 
1997). The function of MMR genes in a cell is to correct errors, such as base-base 
mismatches and insertion-deletion loops (IDLs) that occur during DNA replication. Base-
base mismatches lead to single base substitutions, whereas IDLs affect microsatellites, 
leading to insertion or deletion of repetitive units. This phenomenon is known as 
microsatellite instability (MSI). Approximately 90% of CRCs associated with Lynch 
syndrome display MSI (Aaltonen et al., 1994; Pedroni et al., 1999). Most Lynch 
syndrome families have a mutation in MLH1 and MSH2, while MSH6 and PMS2 are less 
frequently involved (Peltomäki, 2003). MLH1 and MSH2 mutations often generate 
typical Lynch syndrome families which fulfil the Amsterdam criteria, and display high 
degree of MSI (Wijnen et al., 1997). Less typical Lynch syndrome families often display 
mutations in MSH6. In these families the age of onset is higher, and penetrance is lower 
(Miyaki et al., 1997). It has been proposed that mutations in MMR genes MLH3 and 
EXO1 may also underlie Lynch syndrome. However, the available data are limited and 
controversial, thus making a reliable assessment of their role in Lynch syndrome 
predisposition is difficult. (Wu et al., 2001; 2001b; Hienonen et al., 2003; Jagmohan-
Changur et al., 2003). MSI and MMR genes are discussed later in more detail. 
 
 
Muir-Torre syndrome  
Muir-Torre syndrome (MTS) is a variant of Lynch syndrome. In addition to Lynch 
syndrome associated tumors, it includes sebaceous skin tumors (Hall et a., 1994; 
Schwartz and Torre, 1995). About half of MTS patients are affected with CRC. Both 
MLH1 and MSH2 have been observed to harbour mutations in MTS tumors, the 
predominant gene, however, being MSH2 (Kruse et al., 1998). 
 
 
Turcot syndrome 
Turcot syndrome (TS) could be placed under polyposis or non-polyposis syndromes 
depending on the underlying gene. It is a rare disorder which includes colorectal 
polyposis, CRC, and brain tumors; either medulloblastoma or glioblastoma. Families 
with colon polyposis and medulloblastoma are likely to have a mutation in APC gene, 
whereas families with CRC and glioblastoma harbour mutations in MLH1 or PMS2 genes 
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(Hamilton et al., 1995; Mori et al., 1994). PMS2 is seldom mutated in classical Lynch 
syndrome families, and it seems that it is primarily associated with TS (Hamilton et al., 
1995; Liu et al., 2001). 
 
 
2.2 Polyposis syndromes 
 
2.2.1 Adenomatous polyposis syndromes 
 
Familial adenomatous polyposis and Attenuated familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is a well-described autosomal dominant condition 
in which affected individuals develop hundreds to thousands of adenomatous polyps in 
the colon and rectum typically after the first decade of life. If untreated, approximately 
90% of individuals with FAP develop CRC by the time they reach their 40s (Talbot et al., 
2000). FAP patients are also at risk for several extracolonic malignancies such as cancers 
of the thyroid, small intestine, stomach, liver and brain. Benign extracolonic features 
associated with FAP include congenital hypertrophy of the retinal pigment epithelium 
(CHRPE), dental abnormalities, jaw cysts, and osteomas of the skull, mandible, and long 
bones (Lal and Gallinger, 2000). The term Gardner syndrome has been used to describe 
FAP patients who in addition to colorectal polyposis display osteomas, epidermoid cysts, 
and skin fibromas (Gardner and Richards, 1953). Now it's known that features previously 
associated with Gardner syndrome are, with variable expression, observed in FAP 
patients, thus Gardner syndrome should not be considered a genetic variant of FAP. 
 
Most individuals affected with FAP have a mutation in tumor suppressor gene APC 
(Groden et al., 1991; Nishisho et al., 1991). In normal cells APC together with other 
proteins forms a complex which binds to β-catenin and directs it to proteosomal 
degradation. When APC is mutated, β-catenin accumulates in a cell and activates 
transcription of several target genes which promotes tumor formation (Giles et al., 2003). 
The clinical phenotype of FAP patients appears to correlate with the type and location of 
mutation. Classic FAP with the occurrence of thousands of polyps is observed in patients 
who have mutations in APC between codons 169 and 1600. CHRPE is mostly seen in 
individuals with mutations between codons 463-1387 (de la Chapelle, 2004). 
 
Attenuated familial adenomatous polyposis (AFAP) is a milder variant of FAP and is 
characterized by a far fewer polyps (<100) and an age of onset 10 to 15 years later than in 
classical FAP patients. However, the lifetime risk for CRC is still very high (Leppert et 
al., 1990; Spirio et al., 1992). Mutations causing AFAP are mainly located in the extreme 
5', and 3' ends of APC. 
 
 
MYH-associated polyposis  
MYH-associated polyposis is a recently reported autosomal recessively inherited 
condition, which is caused by mutations in DNA repair gene MYH (Al-Tassan et al., 
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2002). Biallelic inactivation, either a homozygous mutation or a compound heterozygote, 
of MYH can lead to a disease that resembles classic FAP, AFAP or Lynch syndrome 
(Enholm et al., 2003; Sieber at al., 2003). MYH is a component of the base-excision-
repair system. MYH deficient tumors display an excess of somatic G:C to T:A 
transversions in APC gene, and this is thought to cause the phenotype of adenomatous 
polyps followed by cancer (Al-Tassan et al., 2002).   
 
 
2.2.2 Hamartomatous polyposis syndromes 
 
Peutz-Jeghers syndrome 
The main feature of Peutz-Jeghers syndrome (PJS) is hamartomatous polyps in the 
gastrointestinal tract. Polyps are mainly located in the small intestine, but can be found in 
colon as well. PJS polyps show a characteristic tree-like structure, which arises when the 
muscular mucosa extends into the polyp. Besides polyps, PJS patients display 
mucocutaneous pigmentation of lips and oral area (Jeghers et al., 1949; Spigelman et al., 
1995). PJS patients are at an increased risk for colon cancer, as well as several other 
malignancies, such as breast, pancreatic, stomach, and ovarian cancer (Giardiello et al., 
2000). The gene predisposing to PJS is LKB1 (STK11), which encodes a serine-threonine 
kinase and appears to function as a tumor suppressor (Hemminki et al., 1998). LKB1 is 
involved in BRG1-dependent chromatin remodeling and in p53 dependent apoptosis 
pathway and VEGF signaling. It also contributes to cell stress sensoring through 
activation of AMPK kinases (Karuman et al., 2001; Marignani et al., 2001; Ylikorkala et 
al., 2001; Hawley et al., 2003).   
 
 
Juvenile polyposis 
Juvenile polyposis (JP) is a child-onset syndrome which is characterized by 
hamartomatous polyps throughout the gastrointestinal tract. Usually juvenile polyps are 
benign, but malignant transformation can occur. Individuals affected with JP have an 
elevated risk mainly for CRC, but also stomach, duodenal, and pancreatic cancers have 
been associated with JP (Järvinen and Franssila, 1984; Järvinen et al., 1993). A variety of 
malformations have been observed in JP patients including congenital heart disease, cleft 
lip/palate, and mental retardation (Järvinen et al., 1993). To date, germline mutations in 
two genes, SMAD4 (DPC4) and BMPR1A, have been detected in JP families. Both are 
components of the transforming-growth factor-β (TGF-β) superfamily (Howe et al., 
1998; Howe et al., 2001). 
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2.3 Low-penetrance alleles predisposing to colorectal cancer 
 
APC I1307K  
Six to seven % of Ashkenazi Jewish individuals carry APC I1307K allele. This variant is 
associated with a 10-20% lifetime risk of CRC (Laken et al., 1997; Gryfe et al., 1999). 
I1307K variant involves a T->A transversion which creates a stretch of eight adenines. 
This may lead to errors in the replication process, causing predisposition to single-
nucleotide insertions or deletions in the (A)8 stretch leading to frameshift mutations. 
Tumor progression is likely initiated when the wild-type allele is somatically mutated in 
APC I1307K carriers (Laken et al., 1997; Zauber et al., 2003). 
 
 
TGFβRI*6A 
The tumor suppressor Transforming growth factor beta (TGFβ) is an efficient inhibitor of 
cell growth. It mediates the growth inhibitory signal through two receptors TGFβRI and 
TGFβRII. TGFβRI has a stretch of 9 alanines within a coding sequence of exon 1. 
Approximately 86% of Caucasian populations are 9A/9A homozygotes, while 14% have 
an allele that is 3 alanines shorter (genotype 9A/6A or 6A/6A) (Pasche et al., 2004). 
Several studies have shown that individuals with at least one 6A allele have a higher risk 
for several cancer types, including CRC (Chen et al., 1999; Pasche et al., 1999; Baxter et 
al., 2002; Pasche et al., 2004). The mechanism by which TGFβ 6A causes a cancer 
predispostion is not known. In a cell line experiments, however, 6A allele have been 
shown to be impaired as a mediator of TGFβ growth inhibitory signals (Chen et al., 1999; 
Pasche et al., 1999).  
 
 
3. PATHWAYS LEADING TO COLORECTAL CANCER      
 
3.1 The suppressor pathway (The adenoma-carcinoma sequence) 
 
The progression of colorectal carcinoma is a multistep process and may take years or 
even decades (Muto et al., 1975). The exceptional feature of CRC is that it is fairly easy 
to collect lesions which precede carcinoma. This has enabled the molecular 
characterization of CRCs at different stages and led to the development of a stepwise 
model of colorectal tumorigenesis referred to as the adenoma-carcinoma sequence 
(Figure 2) (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1996). 
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Figure 2. The adenoma-carcinoma sequence. Mutations in the APC gene initiate the 
neoplastic process, and tumor progression results from mutations in the other genes, such 
as KRAS, TP53, and SMAD4 (Modified from Kinzler and Vogelstein 1996).  
 
 
The adenoma-carcinoma sequence has also been called the suppressor pathway, since the 
tumor initiation and progression requires inactivation of several tumor suppressor genes. 
These tumor suppressor genes are located in chromosomal regions which often appear to 
be deleted in tumor cells. The most frequently deleted chromosome arms in colorectal 
tumors are 5q, 17p, and 18q containing tumor suppressor genes APC, TP53, and SMAD4, 
respectively (Vogelstein et al., 1988; Kinzler and Vogelstein, 1996). 
 
 APC has been proposed to function as a "gatekeeper" gene, regulating the entry of    
colon epithelial cells into the neoplastic process. Already the earliest precursor lesions, 
aberrant crypt foci (ACF), display mutations in APC (Jen et al., 1994). APC protein is a 
part of Wingless (Wnt) signaling pathway. In normal cells, in the absence of Wnt ligand, 
APC forms a complex together with axin and glycogen synthase kinase-3B (GSK-3β). 
This complex binds and phosphorylates β-catenin, and directs it to subsequent 
ubiquitination and degradation (Orford et al., 1997; Giles et al., 2003). When APC is 
mutated β-catenin degradation complex does not take form, and β-catenin accumulates in 
the nucleus. β-catenin is able to bind to the T-cell factor (TCF) family of transcription 
factors which again activate transcription of other tumor promoting genes, such as C-
MYC and cyclin D1 (CCND1) (He et al., 1998; Wong and Pignatelli, 2002).  
 
Wnt signaling pathway may be disrupted also by mutated β-catenin. Approximately half 
of the tumors with wild type APC display mutations in β-catenin encoding gene 
CTNNB1, suggesting that CTNNB1 mutation can substitute APC mutation in colon 
carcinogenesis (Morin et al., 1997; Sparks et al., 1998). It, however, appears that 
mutations in APC and CTNNB1 are not functionally identical, since adenomas with 
CTNNB1 mutations seem not to progress to malignant tumors as likely as adenomas with 
APC mutation (Samowitz et al., 1999a).  
 
An ACF, which results from the initial mutations, eventually acquires additional 
mutations in other genes. Another genetic alteration which occurs early in the adenoma-
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carcinoma sequence is activation of KRAS oncogene (Vogelstein et al., 1988; Shibata et 
al., 1993). Kras is a guanosine 5'-triphosphate (GTP)-binding protein. It is located at the 
cytoplasmic site of a cell membrane, and is involved in transducing signals from receptor 
tyrosine kinases, like epidermal growth factor receptor (EGFR). Downstream elements of 
this pathway include cytoplasmic RAF serine-threonine kinase and mitogen activated 
protein (MAP) kinase (Vogelstein and Kinzler, 2004). K-ras is active, when it is bound to 
GTP but becomes inactive when GTP is hydrolysed to guanosine 5'-diphosphate (GDP). 
Carcinogenic mutations in KRAS affect codons in the GTP-binding domain, resulting in a 
constitutively active protein (Bos, 1988; McCormick, 1989). KRAS mutations occur in 
small adenomas, but it is more common in larger adenomas (Vogelstein et al., 1988; 
Scott et al.., 1993; Rashid et al., 1999). It seems that while mutated KRAS gives cells a 
growth advance it is unlikely an initiating factor in colorectal tumorigenesis. Cells with 
only KRAS mutation form foci of hyperproliferating cells, which have a normal cellular 
organization. These cells appear to have little or no potential to form clinically important 
tumors (Pretlow et al., 1993; Jen et al., 1994). 
 
Chromosome arm 18q is deleted in approximately 50% of colorectal adenomas and 70% 
of carcinomas (Vogelstein et al., 1988; Fearon and Vogelstein 1990). Initially the 
candidate tumor suppressor gene in this region was deleted in colorectal cancer (DCC). 
However, mutant alleles of DCC are seldom observed in CRCs showing 18q loss, and 
mouse studies involving DCC homologue have not been able to demonstrate the tumor 
suppressor function of DCC in cells (Cho et al., 1994; Fazeli et al., 1997). Two other 
tumor suppressor genes, SMAD2 and SMAD4 also reside in chromosome 18q. Smad 
proteins are components of the transforming growth factor-β (TGF-β) signaling pathway 
(Massague et al., 1998). TGF-β signaling has various inhibitory effects in cells, including 
regulation of cell growth, differentiation, and apoptosis (Heldin et al., 1997). Germline 
mutations in SMAD4 predispose to familial colon cancer syndrome juvenile polyposis 
(Howe et al., 1998), and somatic mutations in both SMAD2 and SMAD4 have been 
observed in CRC, as well as in several other cancers (Riggins et al., 1997). Furthermore, 
mutations in TGF-β type II receptor (TGF-βRII) have been detected in 90% of 
microsatellite instable CRCs, supporting the importance of aberrant TGF-β signaling in 
colorectal tumorigenesis (Parsons et al., 1995).  
 
TP53 is frequently altered in various human cancers (Caron de Fromentel and Soussi, 
1992). It resides in the short arm of chromosome 17, which is often deleted also in CRC 
(Vogelstein et al., 1988). p53 is important in maintaining DNA integrity. In the presence 
of damaged DNA, p53 blocks cell proliferation until the damage has been repaired. If the 
damage is too great, p53 is able to induce apoptosis. Loss of function of p53 results in 
accumulation of mutations throughout the genome, karyotypic instability, and reduced 
apoptosis (Lane 1992; Donehower and Bradley, 1993; Carder et al., 1993; May and May, 
1999). TP53 mutation represents a late event in colorectal tumorigenesis, as it tends to 
occur at the late adenoma stage. It, however, seems not to be an absolute requirement for 
malignant transformation, since CRCs develop also without detectable TP53 mutation 
(Baker et al., 1990). 
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3.2 The mutator pathway 
 
Colorectal tumors evolving through the suppressor pathway often show gross 
chromosomal instability (CIN) e.g. losses and amplifications of whole chromosomes. A 
mutator pathway is driven by a defect in DNA repair caused by the inactivation of DNA 
MMR genes (Boland et al., 1998a). CRCs evolving through mutator pathway are usually 
diploid but the deficient DNA repair causes accumulation of genetic alterations especially 
in the repetitive sequences. This phenomenon is called microsatellite instability (MSI) 
(Ionov et al., 1993; Thibodeau et al., 1993). Almost all colorectal tumors from Lynch 
syndrome patients display MSI. However, MSI occurs in approximately 15% of 
unselected CRCs as well. In these tumors MSI is usually due to MLH1 promoter 
hypermethylation (Kane et al., 1997; Cunningham et al., 1998; Herman et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The mutator pathway. The genes mutated in MSI tumors often possess 
repetitive tracts in the coding sequence. 
 
 
Tumor suppressor genes are targets also in the mutator pathway, and a tumor progresses 
from adenoma to carcinoma, but most of the genes underlying CIN and MSI tumors are 
different (Figure 3). The repertoire of tumor suppressor genes mutated in MSI tumors at 
least in part includes genes that possess short repetitive tracts within their coding 
sequences. One such gene is TGF-βRII. It contains an (A)10 repeat in exon 3, which is 
mutated in up to 90% of MSI CRCs (Markowitz et al., 1995; Parsons et al., 1995). TGF-
βRII mutations are present in late adenomas, and in adenomas containing invasive 
carcinoma, suggesting that inactivation of TGF-βRII is an important step in MMR-
deficient CRC progression (Grady et al., 1998). BAX and IGFIIR show frequent mutation 
rates in MSI tumors as well (Rampino et al., 1997, Calin et al., 2000). The target for 
mutations in both BAX and IGFIIR is a (G)8 repeat. BAX is mutated in approximately 
50% of MSI CRCs, while 10-20% of MSI tumors display mutations in IGFIIR (Schwartz 
et al., 1999; Calin et al., 2000; Mori et al., 2001). Bax belongs to a bcl-2 multiprotein 
family, which is a major regulator of apoptosis and consists of both inducers and 
repressors (Hirose et al., 1997). Bcl-2 prolongs cell survival by blocking apoptosis. Bax 
forms heterodimers with bcl-2, and thereby accelerates apoptosis (Krajewski et al., 1994). 
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IGFIIR is a growth factor receptor, which plays an important role in regulating cell 
growth and apoptosis. It participates in lysosomal degradation of a growth stimulating 
protein IGFII, and is required for the activation of TGFβ, an important growth inhibitor 
(Dennis et al., 1991; Ellis et al., 1996). Besides TGF-βRII, BAX, and IGFIIR, repeat 
mutations have been reported in mismatch repair genes MSH3 and MSH6 (Malkhosyan S, 
et al., 1996). Additionally, several other genes have been proposed to be mutated in MSI 
tumors, but the studies on these genes are currently not extensive enough to confirm their 
role in MSI tumorigenesis (Duvald and Hamelin, 2002). 
 
Approximately 30-40% of MSI tumors display mutations in BRAF oncogene 
(Rajagopalan et al., 2002; Domingo et al., 2004). BRAF is a member of RAF family of 
serine/threonine kinases. It mediates responses to growth signals through the RAS-RAF-
MAP kinase pathway (Peyssonnaux and Eychene, 2001).   
 
 
3.3 The serrated neoplasia pathway 
 
The serrated neoplasia pathway may represent a novel route that leads to malignant 
colorectal tumors. Serrated CRCs differ from conventional adenocarcinomas on 
morphology. Epithelium of serrated CRCs show saw-toothed structure similar to 
hyperplastic polyps (Figure 4), thus hyperplastic polyp is thought to be the precursor 
lesion of serrated CRCs. Hyperplastic polyp then progresses to serrated adenoma and 
further to serrated carcinoma (Hawkins et al., 2002) (Figure 5). Serrated CRCs appear to 
be quite rare, accounting for approximately 6% of all CRCs (Mäkinen et al., 2001). Their 
contribution to overall CRC burden thus equals CRCs associated with highly penetrant 
hereditary syndromes.  
 
 
 
 
Figure 4. Hematoxylin-eosin stained sections from conventional (A) and serrated (B) 
adenocarcinomas showing the characteristic saw-toothed epithelium of the latter tumors. 
 
 
Recent studies have tried to clarify molecular changes underlying the serrated pathway. 
The serrated structure may be due to inhibition of apoptosis. Tateyama et al. (2002) 
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observed decreased expression of CD95 (Fas) in cells of the upper crypt. CD95 is a 
transmembrane glycoprotein that belongs to the tumor necrosis factor (TNF) superfamily. 
Binding of Fas-ligand to CD95 is able to induce apoptosis in normal colon cells (Strater 
et al., 1997). Charcteristic serrated morphology takes form as cells continue to proliferate 
but are blocked from ascending to their right location in the colonic epithelium. 
Approximately 20% of serrated adenomas display Wnt pathway abnormalities suggesting 
that a subset of serrated tumors develop along pathways involving changes in APC/β-
catenin (Sawyer et al., 2002). Mutations in BRAF have been observed in serrated 
adenomas and tumors (Kambara et al., 2004). BRAF appears to be mutated early in the 
serrated pathway (Kambara et al., 2004). KRAS mutations, however, appear to be rare in 
serrated lesions since only 15% of serrated adenomas display mutations in KRAS (Sawyer 
et al., 2002). Loss of chromosome 1p may also represent an early event in the serrated 
pathway, since it can be detected already in hyperplastic polyps (Rashid et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The serrated neoplasia pathway leading to CRC.  
 
 
 
4. MICROSATELLITE INSTABILITY 
 
Microsatellites are short tandem repeats of simple sequences that are scattered throughout 
the genome. They typically consist of 10-50 copies of 1 to 6 bp motifs, and are 
characterized by a high degree of polymorphism. The most common repeats in humans 
are mononucleotide repeats (A)n/(T)n and dinucleotide repeats (CA)n/(GT)n. 
Microsatellites usually occur in non-coding regions (Weber and Wong, 1993; Strachan 
and Read, 1999). Microsatellite instability (MSI) is defined as “a change of length due to 
either insertions or deletions of repeat units in a microsatellite within a tumor compared 
to normal tissue” (Boland et al., 1998b). MSI occurs when cells are not able to repair 
base-base mismatches and insertion/deletion loops (IDLs) that arise as a consequence of 
DNA polymerase slippage during DNA replication. Normally mismatch repair (MMR) 
machinery repairs majority of damages in DNA, but in cells with defective MMR system 
the microsatellite mutation rate is highly accelerated (Bhattacharyya et al., 1994). 
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Approximately 90% of CRCs from Lynch syndrome patients show high degree of MSI 
(MSI-H), and it occurs also in 10-15% of sporadic CRCs (Aaltonen et al., 1993; 
Thibodeau et al., 1993; Aaltonen et al., 1994; Liu et al., 1996). Besides previously 
mentioned molecular differences, MSI-H and microsatellite stable (MSS) tumors display 
several clinical and pathological differences. MSI-H tumors are more likely to be poorly 
differentiated, and have a mucinous phenotype. They are more often located in the right 
side of colon, and are associated with female sex. MSI-H tumors also have a better 
prognosis (Ward et al., 2001). In addition to CRC, MSI has also been observed in other 
cancer types such as endometrium, breast, pancreatic, gastric and prostate cancer (Han et 
al., 1993; Burks et al., 1994; Yee et al., 1994; Suzuki et al., 1995).   
 
In 1997 National Cancer Institute workshop on microsatellie instability defined the 
uniform criteria for MSI, and proposed technical guidelines for MSI detection. The 
recommended method to analyze MSI is to study tumor and respective normal tissue 
DNA using a panel of five microsatellite markers; BAT25, BAT26, D2S123, D5S346 
and D17S250. If two or more markers display instability, a sample is designated MSI-H. 
If none of the markers show instability a sample is MSS. If one marker shows instability 
a sample is defined as MSI-L (low-level MSI). In this case additional markers should be 
analyzed to distinguish between MSI-H and MSI-L. If more than five markers are 
analyzed a sample is MSI-H if more than 30% of markers show MSI. The remaining 
cases fall into MSI-L category (Boland et al., 1998). Since MSI is a potential marker for 
Lynch syndrome it is utilized in CRC diagnostics together with immunohistochemistry. 
Tumors from putative Lynch syndrome patients can be analyzed for MSI. If a tumor turns 
out to be MSI-H, the underlying germline MMR mutation can be detected using 
immunohistochemistry and direct sequencing of the gene (Table 3). 
 
 
 
Table 3.  The Bethesda guidelines for the situations when colorectal tumors should be 
tested for MSI 
 
1 CRC diagnosed before age 50 
2 Presence of synchronous, metachronous CRC or other Lynch syndrome associated 
tumor regardless of age 
3 CRC with typical MSI-H histology (e.g. presence of tumor infiltrating lymphocytes, 
Crohn's-like lymphocytic reaction, mucinous/signet ring differentiation, or medullary 
growth pattern) 
4 CRC diagnosed in one or more first-degree relatives with an Lynch syndrome 
associated tumor, with one of the cancers being diagnosed under age 50 
5 CRC diagnosed in two or more first- or second degree relatives with Lynch syndrome 
related tumors regardless of age  
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Whilst MSI-H and MSS tumors clearly form separate CRC subgroups, the role of MSI-L 
tumors have been obscure. MMR genes MLH1, MSH2, and MSH6 appear not to play a 
role in MSI-L tumor development (Percesepe et al., 1998; Thibodeau et al., 1998), and 
clinicopathological features does not differ between MSI-L and MSS tumors. Thus, many 
studies support the combining of these two groups (Mirabelli-Primdahl et al., 1999; 
Gonzales-Garcia et al., 2000; Parc et al., 2001; Ward et al., 2001). Some studies have, 
however, found molecular differences between MSI-L and MSS tumors. Reduced Bcl-2 
expression, excess of KRAS mutations, lower deletion frequency in chromosome 5q, 
higher apoptotic activity and lymphocyte infiltration have been associated with MSI-L 
tumors (Biden et al., 1999; Jass et al., 1999; Michael-Robinson et al., 2001). Methylation 
of MGMT may also play a role in MSI-L tumor formation (Whitehall et al., 2001). The 
usefulness of MSI-L group was controversial already at the beginning. Its existence was, 
however, considered necessary since all genes responsible for MSI are not yet known, 
and some of them may be associated with more attenuated phenotype, like MSH6 
(Akiyama et al., 1997; Wu et al., 1999). Despite that the workshop held in 2002 proposed 
that MSI-L and MSS tumors should not be separated for clinical purposes (Umar et al., 
2004).     
 
 
4.1 Mismatch repair system 
 
MMR system is well conserved in evolution. In Eschricia coli MutS recognises base-base 
mismatches and small IDLs (Modrich and Lahue, 1996). MutL homodimer then forms a 
complex with MutS, and couples mismatch recognition and downstream MMR events 
(Hall and Matson, 1999). Endonuclease mutH makes the discrimination between the 
template and newly replicated strands by introducing a nick in the new hemi-methylated 
strand (Buermeyer et al., 1999). DNA-specific exonucleases, such as RecJ, ExoVII, ExoI, 
and ExoX excise the incorrect DNA sequence (Burdett et al., 2001), and finally DNA 
polymerase III holoenzyme and DNA ligase take care of resynthesis and ligation 
(Modrich and Lahue, 1996). 
 
Eukaryotic MMR system functions largely in a similar manner, but is more complex than 
the system in E. coli. So far five MutS and four MutL homologs have been identified in 
human cells (Table 4).  
 
For mismatch recognition MSH2 forms a heterodimer with either MSH6 or MSH3 
depending on the damage that needs to be repaired. The MSH2-MSH6 complex (MutSα) 
takes care of mismatches and single base IDLs, while the larger 2-4 bp IDLs are 
recognized by either MSH2-MSH3 complex (MutSβ) or MutSα. (Acharya et al., 1996; 
Marsischky et al., 1996; Edelmann et al., 2000; Jiricny 2000). A heterodimer of MLH1 
and PMS2 (MutLα) interacts with mismatch recognition complexes (MutSα) and 
(MutSβ), and mediates the actual mismatch repair (Prolla et al., 1994; Wang et al., 1999) 
(Figure 6). 
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Table 4. MMR gene homologs in E.coli and humans, and the distribution of mutations 
detected in Lynch syndrome families (http://www.insight-group.org; The pathogenicity 
of each mutation has not been confirmed) 
E.coli H.sapiens No of detected mutations 
MutS MSH2 175 (38.5%) 
 MSH3 - 
 MSH4 - 
 MSH5 - 
 MSH6 32 (7.0%) 
   
MutL MLH1 225 (49.5%) 
 MLH3 16 (3.5%) 
 PMS1 1 (<0.1%) 
 PMS2 5 (1.1%) 
 Total 454 (100%) 
  
 
 
Human MMR complex most likely contains several other proteins. Like the repair system 
in E.coli endonuclease, exonuclease, DNA polymerase, and ligase are probably required 
in human MMR as well. The mechanism for strand discrimination in humans is unclear. 
No MutH endonuclease homologs have been identified in humans so far, and the only 
exonuclease known to act in MMR is exonuclease 1 (EXO1) (Schmutte et al., 1998; 
Tischkoff et al., 1998). MSH4 and MSH5 are not needed in the actual MMR, but are 
necessary for meiotic recombination (de Vries et al., 1999; Edelmann et al., 1999). The 
role of PMS1 in MMR awaits further research.  Besides DNA repair, the MMR system 
plays an important role in signaling the presence of DNA damage to the apoptotic 
machinery (D’Atri et al., 1998; Hickman and Samson, 1999). This may explain why 
MMR deficient tumors are more resistant to DNA modifying drugs than their MMR 
proficient counterparts (Karran and Hampson, 1996; Fink et al., 1999). 
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                  Mismatches                 Insertion/deletion loops                          
 
 
                 ATGGACCTAA                                             CACACACACACACA  
                 TACCGGGATT                                              GTGTGTGTGTGTGT 
 
                                                                                                        GT 
 
 
 
 
                                                                                                                    
                                                                                                                    
 
 
 
 
 
 
                  ATGGCCCTAA                                             CACACACACACACA 
                  TACCGGGATT                                             GTGTGTGTGTGTGT 
 
 
Figure 6. Human MMR system  
 
 
4.1.1 Defects in the mismatch repair system 
 
The majority of MMR gene defects that predispose to Lynch syndrome are in either 
MLH1 or MSH2 (approximately 50 and 40%, respectively) (International Collaborative 
Group on Hereditary Non-Polyposis Colorectal Cancer http://www.insight-group.org). 
Mutations in both genes are located in all regions without obvious hotspots. In Finland 
two founder mutations account for the majority of Lynch syndrome mutations. Mutation 
1 is a 3.5 kb genomic deletion causing an in-frame 165 bp deletion comprising MLH1 
exon 16. Mutation 2 is a splice acceptor mutation in MLH1 leading to the deletion of 
exon 6, and causing frame-shift and a premature stop codon (exon 6, G->A at 454-1) 
(Nyström-Lahti et al., 1995). Approximately 10% of Lynch syndrome patients have 
mutation in MSH6 (http://www.insight-group.org). MSH6 mutations are associated with 
atypical Lynch syndrome with later age of onset, lower penetrance, and lower degree of 
MSI in tumors. In females truncating mutation of MSH6 seems more likely to predispose 
to endometrium cancer than CRC (Wijnen et al., 1999). PMS2 mutations are rare. To date 
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only five mutations have been reported in the HNPCC mutation database 
(http://www.insight-group.org).  
 
The role of MMR genes MLH3 and EXO1 in Lynch syndrome is not clear. Germline 
mutations have been found in both genes but subsequent studies have proven that many 
of the reported mutations occur in healthy controls as well. Further studies are needed to 
thoroughly clarify the role of these genes in cancer predisposition (Wu et al., 2001; Wu et 
al 2001b exo; Hienonen et al., 2003; Jamoghan-Changur et al., 2003). 
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AIMS OF THE STUDY 
 
 
 
1. To study the capability of the mononucleotide marker BAT26 to detect mutation 
positive HNPCC patients compared to the recommended Bethesda microsatellite 
marker panel.  
 
2. To clarify the molecular character of MSI-L tumors and the functionality of the 
Bethesda panel in detecting MSI-L tumors.  
 
3. To identify new chromosomal regions for low and moderate penetrance genes 
predisposing to CRC. 
 
4. To study the molecular background of CRCs displaying serrated histology. 
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MATERIALS AND METHODS 
 
 
1. PATIENT SAMPLES (I, II, III, IV) 
 
Approximately 1500 fresh frozen CRC samples have been collected in hospitals mainly 
located in Eastern Finland between May 1994 and December 2004. Of these 1042 tumors 
were a part of consecutively collected sample set that has been described by Aaltonen et 
al., 1998 and Salovaara et al., 2000. Samples selected for each study were a part of this 
collection. All samples have been analyzed for MSI using BAT26 and TGFβRII. All MSI 
samples have been analyzed for the two most common MMR gene mutations in Finland 
(see page 29). If neither mutation has been detected, mutation analysis of MLH1 and 
MSH2 has been performed using direct sequencing of the coding exons. Background 
information, such as sex, age at diagnosis, tumor stage, grade, and location of all patients 
has been carefully documented. First degree relatives have been identified through parish 
and population registries and their cancer status obtained from Finnish Cancer Registry. 
In study IV additional samples were used from a collection described by Mäkinen et al., 
2001. The study was approved by Ministry of Social Affairs and Health and the Ethics 
committee of the Department of Medical Genetics, University of Helsinki. 
 
 
1.1 DNA (I, II, III, IV) and RNA (IV) extraction 
 
DNA was extracted from fresh frozen tumors. A pathologist evaluated the proportion of 
tumor tissue in samples prior to DNA extraction to confirm that the maximal amount of 
tumor tissue was used. Samples typically displayed over 60% of tumor tissue. None of 
the samples displayed less than 50% of tumor tissue. Respective normal DNA was 
extracted either from normal colon mucosa or peripheral blood. A standard non-
enzymatic method was used (Lahiri and Nürnberg, 1991). 
 
For RNA extraction the tissue was first homogenized using Ultra Turrax homogenizer. 
Samples were subsequently treated with Trizol reagent (Gibco BRL, Long Island, NY) 
and cleaned with RNeasy spin columns (Qiagen, Valencia, CA). The quality of the RNA 
was confirmed using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).  
 
 
2. MSI ANALYSIS (I, II) 
 
The MSI status of samples used in study I and II was analyzed using the five 
microsatellite markers BAT25, BAT26, D2S123, D5S346, and D17S250 recommended 
by the International Workshop (Boland et al., 1998). In study II MSI analysis was 
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continued with 372 markers (ABI PRISM Linkage Mapping Set MD-10, P/N 450067). 
All markers were run in ABI PRISM 377 DNA Sequencer (Applied Biosystems (AB) 
Division, Foster City, CA), and the data was analyzed using either GeneScan 3.1 or 
Genotyper 2.5 softwares. The results were always evaluated by more than one individual. 
In cases of any ambiguity a previously presented mathematical model was used to score 
for MSI (Canzian et al., 1996). 
 
 
3. IMMUNOHISTOCHEMISTRY AND MUTATION ANALYSIS OF 
MLH1, MSH2 AND MSH6 (I) 
 
Immunohistochemical staining of MLH1, MSH2, and MSH6 were performed to study the 
protein expression in 20 MSI-L and 2 novel MSI-H cases appearing in the microsatellite 
analysis. The details of immunohistochemistry are explained in study I. 
 
The 2 novel MSI-H cases were sequenced for mutations in MLH1 and MSH2 genes using 
previously described primers (Chadwick et al., 2001). To exclude the possibility of large 
deletions MLH1 and MSH2 were analyzed using Southern blotting. Genomic DNA was 
digested using EcoRI and analyzed with two cDNA probes designed for MLH1 and 
MSH2, respectively. The two new MSI-H cases were also analyzed for mutations in 
MSH6. The primer sequences and PCR conditions used to amplify the 10 exons of MSH6 
are listed in Table 5. Exon 1 was amplified in 2, and exon 4 in 8 overlapping fragments. 
Primer sequences were designed using the Primer3 server (http://Frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi).  Direct sequencing of all three genes was performed 
using Big Dye 3 Terminator chemistry, and reactions were run on ABI 3100 capillary 
sequencer (AB). The frequency of the variant observed in MSH6 exon 2 in one of the 
MSI-H cases was analyzed in 182 cancer-free control individuals and 83 CRC patients by 
single strand conformational polymorphism (SSCP). The SSCP procedure is described in 
study I. 
 
 
4. LOCUS SPECIFIC LOH ANALYSIS (II) 
 
LOH at three different loci in chromosomes 5q, 17p, and 18q was analyzed using five 
microsatellite markers: D5S318, D5S346, TP53, D18S1156, and D18S363. The primer 
sequences for markers were: D5S318F: AGGATCTTCCCTCTTTCTCTCTG R: 
GGCATCTATGTTGATGGGATCTATC TP53F: ACTGCCACTCCTTGCCCCATTC 
R: AGGGATACTATTCAGCCCGAGGTC D18S1156F: CCTGCAAGTTTACTGGC R: 
CAATGACAACCTGTTGTTGG D18S363F: TTGGGAACTGCTCTACATTC R: 
GCTTCATTCTCTCACTGGAT. Primer sequences for D5S346 are listed in Table 1 in 
study I. PCR conditions as well as ABI PRISM 377 run were similar to the marker 
D5S346, and are described in study I.      
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Table 5. Primer sequences and PCR annealing temperature for the MSH6 gene 
Exon Primer sequence Annealing temperature 
Exon 1aF tcc gtc cga cag aac ggt tg 
Exon 1aR ttc gcg tga ggc cct ggc cga 
56°C  
 
Exon 1bF cgc tga gtg atg cca aca ag 
Exon 1bR caa ccc cct gtg cga gcc tc 
56°C  
 
Exon 2F tgc cag aag act tgg aat tg 
Exon 2R cac aca cac atg gca gta gtg a 
57°C  
 
Exon 3F tgc tgg gat tac agt cgt ga 
Exon 3R tcc ccc atc acc cta aca ta 
59°C  
Exon 4aF gaa aaa cag tgg ctg cac g 
Exon 4aR gag cca ttt cca gtc acc at 
57°C  
 
Exon 4bF tgg agt ggg gga tag tga ga 
Exon 4bR cac ttc ctc atc cca gga gt 
57°C  
 
Exon 4cF atc acc ccg att ttg atg c 
Exon 4cR gga tca cct tcc agc aca ct 
55°C  
Exon 4dF gga tca tta cca agg gta cac a 
Exon 4dR gcc atc act tag ctt ttc cc 
55°C 
Exon 4eF ata ccc ggc tcc cag ttt t 
Exon 4eR cct ctc tag tag ggt tcc ttc agt 
55°C  
Exon 4fF gcc tat caa cga atg gtg ct 
Exon 4fR ttt gaa tc ttc cag agc aga 
55°C  
Exon 4gF ccc aga cag cag ggc tat aa 
Exon 4gR gtt cct acc aat ccc cca cca at 
55°C  
Exon 4hF tga aca gag cct cct gga at 
Exon 4hR agc tgg caa aca gca cta ctt 
57°C  
 
Exon 5F taa aac ccc caa acg atg aa 
Exon 5R gga gta att tcc ctt tgc ttc c 
55°C 
Exon 6F gtt tat gaa act gtt act acc 
Exon 6R gca aat atc ttt tat cac at 
53°C  
Exon 7F gag tat tca ttt gtg att tt 
Exon 7R cgc cca tgt ttt taa gat agt agt ctt c 
55°C  
Exon 8F ccg atg ttg ctt ttc tgt cc 
Exon 8R cag aag tgc cct ctc aaa aa 
55°C  
Exon 9F gag agg gca ctt ctg ttg ct 
Exon 9R cac tag cca ggc aaa ctt cc 
55°C  
Exon 10F gga agg gat gat gca cta tga 
Exon 10R tgt tgt ctg aat tta cc acct ttg 
55°C  
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5. MUTATION ANALYSIS OF KRAS (II) 
 
Mutation hotspots in KRAS codons 12, 13, and 61 were screened by direct sequencing of 
exons 1 (codons 12 and 13) and 2 (codon 61) as described previously (Servomaa et al., 
2000). Direct sequencing was performed using Big Dye 3 Terminator chemistry, and 
reactions were run on ABI 3100 capillary sequencer (AB). Sequence chromatograms 
were analyzed using EditView 1.0.1 Software (AB).   
 
 
6. MGMT, MLH1, AND EPHB2 PROMOTER 
HYPERMETHYLATION ANALYSIS (II, IV) 
 
DNA methylation patterns in the CpG islands of MGMT, MLH1, and EPHB2 promoter 
regions were determined by chemical modification of unmethylated, but not methylated 
cytocines to uracil, and subsequent PCR using primers specific for either methylated or 
the modified unmethylated DNA.  
 
6.1 Bisulfite modification 
 
One µg DNA was denatured by 0.2 M NaOH for 10 min at 37°C. Thirty µl of 10 mM 
hydroquinone (Sigma, St. Louis, MO) and 520 µl of 3 M sodium bisulfate (Sigma) at pH 
5, both freshly prepared, were added and mixed, and samples were incubated under 
mineral oil at 50°C for 16 hours. Modified DNA was purified using Wizard DNA 
purification resin (Promega, Madison, WI) and eluted into 50 µl of water. Modification 
was completed by 0.3 M NaOH treatment for 5 min at room temperature, followed by 
ethanol precipitation. DNA was resuspended in water and used immediately or stored at -
20°C. 
 
6.2 Methylation specific PCR 
 
Methylation specific primers for MGMT and MLH1 have been described previously 
(Herman et al., 1998; Esteller et al., 1999), primers for EPHB2 are described in study IV. 
Primers have been designed to amplify either methylated or unmethylated bisulfite 
modified DNA. CRC cell line SW48 was used as a positive control and DNA from 
normal lymphocytes as a negative control for methylated alleles of MLH1 and MGMT. 
For EPHB2 in vitro methylated DNA (Chemicon International, Temecula, CA) was used 
as a positive control for methylated alleles, while paired normal tissue DNA was used as 
a negative control. Ten µl of each PCR reaction was directly loaded onto non-denaturing 
6% polyacrylamide gels, stained with ethidium bromide, and visualized under UV 
illumination. 
 35
7. TOPOGRAPHIC MUTATION HETEROGENEITY ANALYSIS (II) 
 
To study the possible topographic mutation heterogeneity of the observed MSI shifts, 
stained microscopic sections from three MSI-L cancers were subdivided by 
microdissection into 6-10 small subregions. The sizes of the microsatellite alleles present 
in each subregion were determined by electrophoresis with 6% acrylamide sequencing 
gels after incorporating [33P]dCTP during PCR. In addition, DNA from whole tumors 
was diluted to essentially single molecules prior to PCR to see if intratumor microsatellite 
mutation heterogeneity was present.   
 
 
8. ALLELIC IMBALANCE (AI) ANALYSIS (III) 
   
The analysis was done in three parts: First, the 104 CRC samples (29 familial and 75 
sporadic cases, sample set S1) were analyzed with 372 CA-repeat markers (ABI PRISM 
Linkage Mapping Set MD-10, P/N 450067, 10 cM density, Applied Biosystems (AB) 
Division, Foster City, CA). PCR reactions for all these markers were carried out in 5 µl 
reaction volume containing 20 ng of genomic DNA, 1 × AmpliTaq Gold PCR buffer 
(AB), 250 µM each deoxynucleotide triphosphate (Amersham Pharmacia Biotech, NJ), 
1,7 pmol each primer, 2,5 mM MgCl2 and 0.4 units of AmpliTaq Gold polymerase (AB). 
PCR cycles were 95°C for 12 min, 10 cycles at 94°C for 30 s, 55°C for 30s and 72°C for 
30s, 20 cycles at 89°C for 30s, 55°C for 30s and 72°C for 30s. The final extension was 
72°C for 10 min. PCR products were run in ABI PRISM 377 DNA Sequencer (AB) 
according to manufacturer´s protocols and the collected data was analyzed by GeneScan 
3.1 and Genotyper 2.5 software (AB). To score for AI, a previously presented 
mathematical model was utilized. AI was scored if an allele was relatively decreased or 
increased by more than 40% (Canzian et al., 1996).  
 
To further evaluate the initial findings the sample set was extended with 59 familial and 
64 sporadic cases (sample set S2). Loci were selected for further analyses when the 
following criteria were fulfilled: The AI percentage at a marker locus was 10 units or 
greater (e.g. 20% versus 30% AI cases) in the familial group, and at least one adjacent 
marker showed such difference as well. From these clusters the locus showing the 
greatest difference was further analyzed. Also two loci which showed 30 percent units 
more AI in the familial group were included.  
 
Third, 47 additional sporadic and 11 familial cases (Sample set S3) were analyzed with 
the markers showing significant AI difference after combined analysis of sample sets S1 
and S2. S1, S2, and S3 comprised in total 285 CRC samples, 99 of which were familial 
and 186 sporadic. One locus was further evaluated in CRC samples from Danish (n=42) 
and UK (n=163) populations. 
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9. COMPARATIVE GENOMIC HYBRIDIZATION (CGH) (III) 
 
To characterize genomic imbalances in familial CRCs, 26 tumors were examined by 
CGH. Tumor DNA and normal reference DNA were labeled by nick translation with 
fluorescein-isothiocyanate-conjugated dCTP and dUTP (DuPont, Boston, MA) and 
Texas-red-conjugated dCTP and dUTP (DuPont). The hybridization was analyzed using 
an Olympus fluorescence microscope mounted to a CCD camera and the ISIS digital 
image analysis system (MetaSystems, Altlussheim, Germany). Three-color images (green 
for tumor DNA, red for reference DNA, and blue for chromosome counterstaining) were 
acquired from 8-10 metaphases with strong uniform hybridization. Chromosome regions 
were interpreted as over represented when the green-to red ratio was higher than 1.17 
(gains) and underrepresented when the ratio was lower than 0.85 (losses). 
 
 
10. REAL–TIME QUANTITATIVE PCR 
 
To further study the proportion of 20q amplification in both familial and sporadic tumors, 
the 26 familial tumors included in the CGH study, and 26 sporadic cases were analyzed 
by real-time quantitative PCR. The relative DNA copy numbers were determined as 
previously described by Ginzinger et al. (2000). For reference, three microsatellite loci, 
D10S586, D11S1315, and D21S1904) were chosen in genomic regions that usually did 
not show alterations in the genome-wide study. 
 
 
 
11. STATISTICAL ANALYSES (II, III) 
 
The statistical analyses used in studies II and III are described in the respective works. 
 
 
12. ARRAY ANALYSIS (IV) 
 
RNA from 8 serrated and 29 conventional adenocarcinomas was first transcribed into 
double stranded cDNA. Biotin labeled cRNA was synthesized from cDNA using a 
labeling kit containing biotin-labeled UTP and CTP in addition to unlabeled 
ribonucleotides. Purified and fragmented cRNA was hybridized onto oligonucleotide 
arrays overnight in constant rotation. After hybridization, arrays were washed, stained 
with streptavidin-phycoerythrin, and scanned. The arrays were initially analyzed with 
Microarray Suite 5.0 software (Affymetrix Inc., Santa Clara, CA). The array analysis is 
described in detail in study IV. 
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13. ARRAY DATA ANALYSIS (IV) 
 
13.1 Normalization and filtering    
 
The expression data was normalized in three steps: 1) data transformation where values 
below 0.01 were set to 0.01 to enable logarithmic transformation, 2) centering of arrays 
where each measurement was divided by the median (50th percentile) of all 
measurements in that sample, and 3) centering of gene intensities where each gene was 
divided by the median of its measurements in all samples. After normalization the data 
was filtered using Affymetrix flag calls (Absent, Present Marginal), so that the program 
allowed inclusion of all genes that had Present or Marginal flag in at least 29 samples. 
After filtering 7928 probe sets remained in the data analysis. Normalization and filtering 
were performed using GeneSpring 6.2.1 software (Silicon Genetics, Redwood City, CA). 
 
 
13.2 Unsupervised hierarchical clustering and identification of differentially 
expressed genes 
 
To study whether serrated CRCs had a different overall gene expression when compared 
to conventional adenocarcinomas an unsupervised hierarchical clustering of the filtered 
7928 probes was done using Spearman’s Rank Correlation as a similarity measure.  
 
A Student’s t-test and Benjamini and Hochberg multiple testing correction was used to 
analyze differentially expressed genes between serrated and conventional CRCs. Both of 
the above mentioned analyses were done using GeneSpring. 
 
 
13.3 Class prediction 
 
Class prediction method was used to find a set of differentially expressed genes (probes) 
between the serrated and non-serrated CRCs that could predict whether an unknown 
sample was a serrated or a conventional tumor. The predictor was created using 4413 
probes that had a Present or Marginal flag call (MAS5) in all of the 37 samples. The 
predictor was built and validated in GeneCluster2 software using a K-Nearest Neighbors 
(KNN) algorithm. Validation of the predictor was performed using a leave-one-out cross-
validation method. 
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14. IMMUNOHISTOCHEMISTRY (IV) 
 
The array results were validated in a larger dataset by immunohistochemistry. The 
sample set was divided into two separate sets: training set (TS) consisted of the 37 
samples hybridized on arrays (8 serrated and 29 conventional CRCs), validation set (VS) 
consisted of additional 37 serrated and 86 conventional CRCs. Six genes, ephrin type-B 
receptor 2 (EPHB2), patched (PTCH), hypoxia-inducible factor 1-alpha (HIF1α), Cyclin 
T2 (CCNT2), metastasis associated-1 (MTA1), and methyl-CpG binding domain protein 4 
(MBD4) that were differentially expressed between serrated and conventional CRCs were 
chosen for staining. Besides the difference in expression level these genes were 
biologically relevant, and the antibody was commercially available. The details of the 
immunohistochemistry are provided in study IV.  
 
 
15. MUTATION SCREENING OF EPHRIN TYPE-B RECEPTOR 2 
(EPHB2) (IV)   
 
15.1 Direct sequencing 
 
Twenty-four serrated samples were screened for mutations in the coding region of 
EPHB2. Primers were designed using Primer3 server (http://Frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi).  The primer sequences and PCR conditions are listed in 
Table 6. Exon 3 was amplified in two fragments, and exons 16 and 17 in one fragment. 
Purified PCR products were run on ABI 3730 sequencer (AB), and sequence 
chromatograms analyzed using BioEdit Sequence Alignment Editor 7.0.1.  
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Table 6. Primer sequences and PCR annealing temperature for EPHB2 gene 
Exon Primer sequence Annealing temperature 
Exon 2F ccgggagagaccactgct 
Exon 2R cctcctcctggcacagtca 
TD 64°C->61°C* 
Exon 3aF gggttccctaaggcagagtc 
Exon 3aR cacttgcggtagaagacacg 
TD 62°C->60°C* 
Exon 3bF tgaaggtggataccattgcag 
Exon 3bR agtctgcagccaagaccagt 
TD 64°C->61°C* 
Exon 4F cctagacagctcacggacaag 
Exon 4R tccatttctcttcccaccag 
62°C 
Exon 5F tttctctggtggggagacag 
Exon 5R ggaccgatcacatgaaaagc 
62°C 
Exon 6F ttgatgtggcctgagcttc 
Exon 6R cagtgctctttctgctgcac 
62°C 
Exon 7F agggaggggatgaagaattg 
Exon 7R acaacgggaacagaaacagg 
62°C 
Exon 8F aggattggagcagttcatgg 
Exon 8R tcggttcaccagcactgtag 
62°C 
Exon 9F gacttgaggtgggaggagtg 
Exon 9R cttgcaaaggcctagaggtg 
62°C 
Exon 10F ctcagctgctccagaaaacc 
Exon 10R tcccacatcctaccttctgc 
62°C 
Exon 11F atgagtgggccattgagaag 
Exon 11R ctgccatggataagggaatg 
59°C 
Exon 12F ccactctgaagttggcctct 
Exon 12R ggagagatggacactcatgc 
TD 61°C->59°C* 
Exon 13F aaatgcccagtggtctgaag 
Exon 13R gaagacgtgctgatgtgtgg 
62°C 
Exon 14F ccaggaggtgaaagtggttg 
Exon 14R cccaagctgcagtaaggaag 
62°C 
Exon 15F acgtgcacattcacgcatac 
Exon 15R gtgagaaaacggaggctgag 
59°C 
Exon 16-17F cttgctttgccatcttcctc 
Exon 16-47R gacacatcgcatgaatctcc 
TD 62°C->60°C* 
*TD = Touch down from one temperature to another, decreasing 0.5°C/cycle 
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RESULTS 
 
 
1. COMPARISON BETWEEN BAT26 AND THE BETHESDA PANEL 
(I) 
 
1.1 MSI analysis using the Bethesda panel  
 
 Out of 494 patients analyzed 73 had shown MSI when previously analyzed with BAT26 
only, and 27 patients had an underlying MMR gene mutation (Aaltonen et al., 1998; 
Salovaara et al., 2000). All of these classified as MSI-H after applying all the five 
Bethesda markers. Altogether 95 of 494 patients classified as MSI when the Bethesda 
panel was used: 75 (15.2%) of patients classified as MSI-H, and 20 (4.0%) patients 
classified as MSI-L. Sequencing of coding regions, exon-intron boundaries and promoter 
regions of MLH1 and MSH2 genes of the 2 novel MSI-H cases revealed no mutations. 
Neither did we detect any aberrant bands in Southern blot which was used to study the 
possibility that large deletions would have caused the MSI-H phenotype. One of the 
novel MSI-H patients, however, displayed a previously reported missense mutation in 
MSH6 exon 2: S144I (AGC->ATC). We analyzed 83 CRC patients and 182 cancer-free 
controls with SSCP for the change and found it in one control sample. The tumor 
harboring the variant showed no loss of heterozygosity at this change. 
 
Additionally, the 22 novel MSI cases appearing in this study were studied for MLH1, 
MSH2, and MSH6 protein expression using immunohistochemistry. All samples scored 
positive (++, +++, or ++++) in the staining. 
 
BAT26 was able to identify all 27 MMR gene mutation positive individuals in the sample 
set. It failed to identify 2 MSI-H cases and 20 MSI-L cases. No MMR deficiency was 
observed in these samples.  
 
 
2. ANALYSIS OF LOW-LEVEL MSI (II) 
 
2.1 MSI analysis 
 
Altogether 90 samples were analyzed for MSI using 377 microsatellite markers. After the 
initial analysis with the Bethesda markers 6 of the 90 tumors (7%) displayed MSI. The 
addition of eight markers listed in the Bethesda reference panel resulted in 9 of 90 (10%) 
tumors showing MSI. After analysis with all 377 markers 71 tumors had displayed MSI. 
Out of 90 tumors 19 did not show MSI at all. The number of mutated loci varied from 1 
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to 11 (see figure 2 in study IIa). Only dinucleotide markers displayed MSI, none of the 
samples was unstable with mononucleotide markers BAT25 or BAT26. The most 
sensitive markers were D6S441 and D10S217. They detected six and five positive 
lesions, respectively. 
 
Topographical distribution of the microsatellite mutations were studied in three tumors 
showing instability with 9-11 markers. The lack of widespread allelic or topographical 
mutation suggests that most microsatellite mutations were acquired before final clonal 
expansion. Topographical heterogeneity was present only at two of six loci from a single 
cancer. When tumor DNA was diluted before PCR no variation in mutation size was 
observed.  Thus, it appears that only single somatic mutation was present throughout the 
tumor. 
  
        
2.2 Comparison between putative MSI-L and MSS groups 
 
Several molecular and clinical differences, including locus specific LOH frequency, 
KRAS mutation frequency, promoter methylation of MGMT and MLH1, sex, age, family 
history of CRC, tumor site, stage, and grade, were studied to analyze if there were 
differences between MSI-L and MSS tumors. All eleven possible cutoff levels for MSI 
were used to see whether significant associations existed (see Table 1 in study IIa). None 
of the examined molecular features were statistically significantly different between the 
two groups. When MSI cutoff was set between zero and one or more mutated markers, 
chromosome 5q was deleted in 16% of MSS cancers vs. 36% in MSI-L cancers (p=0.10), 
chromosome 17p was deleted in 38% of MSS cancers vs. 53% in MSI-L cancers 
(p=0.40), and chromosome 18q was deleted in 60% of MSS cancers vs. 27% in MSI-L 
cancers (p=1.0). KRAS mutation frequency was 37% among MSS tumors and 31% 
among MSI-L tumors (p=0.26), giving no implication that MSI-L tumors would have 
higher KRAS frequency. Neither did we observe any association between MSI frequency 
and KRAS mutation status (p=0.78). MGMT promoter was methylated in 11% of MSS 
tumors and 27% of MSI-L tumors, while MLH1 promoter was methylated in 5% of MSS 
tumors and 10% of MSI-L tumors (p=1.0). 
 
There was no evidence for a relationship between MSI-L status and either tumor stage, 
location or family history of cancer. The only statistically significant relationship 
between grade and MSI-L status was observed in tumor grade, when the cutoff for MSI 
was set to <3 (p=0.01 using 0 as a cutoff). When patient age at tumor removal was 
plotted with respect to the relative frequency of microsatellife mutation, there was a 
significant relationship between age and frequency of MSI (p=0.012) (see Figure 3 in 
study IIa). It, thus, appears that older patients tend to have more microsatellite mutations. 
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3. ALLELIC IMBALANCE IN FAMILIAL AND SPORADIC 
TUMORS (III) 
 
3.1 AI analysis 
 
In step one, we analyzed 29 familial and 75 sporadic CRCs (sample set S1) for AI , using 
a genome-wide panel of 372 microsatellite markers. Overall, AI varied from 0 to 59% 
between markers. AI was especially frequently observed in chromosomes 5q, 17p, and 
18q. Previous studies have shown that these regions are often deleted in CRCs. After the 
first step several loci appeared, in which familial tumors showed more AI when 
compared to sporadic tumors. Odds ratios (ORs) were computed for each of the 22 
autosome markers. Figure 2 in study III shows crude ORs and associated 95% confidence 
intervals for individual marker loci. After analysis of the first 104 samples ORs were 
significantly increased for five chromosome regions in the familial group: 7q21.3, 
14q24.3, 20p12.2, 20q13.1, and 20q13.3. The most promising regions were in 
chromosome 20.   
 
In step two to see if the observed differences held in a larger data set the sample set was 
extended with an additional 59 familial and 64 sporadic CRCs (sample set S2). Ten 
promising loci identified in step one were analyzed and the OR associated with each 
marker recomputed. The only significant relationship between AI and family history was 
seen with the three chromosome 20 loci. These markers were chosen for step 3. 
 
In the third step the three chromosome 20 markers, D20S186 in 20p12.2, D20S178 in 
20q13.1 and D20S171 in 20q13.3 were analyzed with set S3, which consisted of an 
additional 11 familial and 47 sporadic CRCs. After the third step the OR for D20S186 
was 1.72 (p=0.06; 95%CI: 0.98-3.03), for D20S171 the OR was 1.97 (p=0.078; 95%CI: 
0.93-4.18), and for D20S178 the OR was 2.74 (p=0.002; 95%CI: 1.44 - 5.20). After 
analyzing 99 familial and 186 sporadic CRCs altogether, the relationship between AI in 
familial risk remained significant in chromosome 20q13.1. The difference was present in 
a small Danish sample set. Out of 10 informative familial cases 8 showed AI at D20S178 
when compared with 1 out of 11 in sporadic tumors (p=0.002). However, no difference in 
AI was detected in a larger sample set from UK.  
 
 
3.2 Comparative genomic hybridization and DNA copy number measurement 
 
To study whether interesting chromosomal regions were lost or amplified, 26 familial 
CRCs were analyzed by CGH. The CGH results are presented in Table 7. It appeared that 
the mechanism underlying AI in chromosome 20 was amplification. 
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Table 7. The most frequently altered chromosomal regions detected by CGH 
Chromosome         Minimal overlapping             Proportion of tumors  
arm                         region                                    showing alteration 
Lost chromosomal regions 
18q 18q22-qter 81% 
14q 14q12-23, 14q24-32 39% 
8p 8p21-pter 23% 
4q 4q21-qter 23% 
Amplified chromosomal regions 
20q 20q11.2-q12 77% 
13q 13q13-q21 50% 
7p 7p21-pter 39% 
7q 7cen-q21 39% 
8q 8q24.1-qter 27% 
 
 
The DNA copy numbers in the sample set was studied using quantitative real-time PCR. 
The copy numbers in the familial group varied from 2 to 5 and in the sporadic group from 
1 to 14. The mean values in the respective groups were 3 and 4. In all, 72% (18/26) of 
familial and 73% (19/26) of sporadic cases were defined as amplified.  
 
 
4. GENE EXPRESSION PROFILE OF SERRATED CRCs (IV) 
 
The unsupervised hierarchical clustering was performed using 7928 probes. All serrated 
samples except for one clustered in the same branch. The only feature that clearly 
separated samples was the histology, no clustering according to any other parameter, like 
stage, grade or sex was observed (see Figure 1 in study IV).  
 
Multiple test corrected Student’s T-test revealed 226 probes (201 genes, and 7 
hypothetical proteins or ESTs) that were statistically significantly differentially expressed 
between serrated and conventional CRCs (p<0.05). The most significantly enriched 
functional categories in the list of 226 differentially expressed genes were morphogenesis 
(p=0.0002), organogenesis (p=0.0002), integral to membrane (p=0.0035), and membrane 
(p=0.0049). 
  
We also created a predictor that could predict the subtype (serrated or conventional CRC) 
of an unknown sample. The predictor consisted of 27 probes, which are listed in 
Supplementary table 5 in study IV. Using these probes the cross-validation procedure 
was able to predict the subtype of an unknown tumor with 100% accuracy. 
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4.1 Immunohistochemistry 
 
To validate the array results, four differentially expressed genes, EPHB2, PTCH, HIF1α, 
and CCNT2 were immunohistochemically stained in 160 samples (45 serrated and 115 
conventional tumors) that were divided into a training set (TS) and a validation set (VS). 
Additionally, the whole TS but only a subset of the VS (in total 59 tumors) was stained 
for MBD4 and MTA1.  
Normal colon mucosa showed positive nuclear staining for Cyclin T2, MTA, and MBD4, 
and positive cytoplasmic staining for EphB2 and Patched. In normal mucosa HIF1α was 
negative.  
Serrated CRCs typically showed weak immunoreaction for EPHB2 (in TS p=0.001, in 
VS p=0.029, chi-square), diffuse and weak immunoreaction for PTCH (staining pattern 
p=0.01, staining intensity p=0.693 in TS, respectively, staining pattern p=0.0003, staining 
intensity p=0.006 in VS, respectively) and frequent positivity for HIF1α (in TS p=0.021, 
in VS p=0.00006). Additionally, serrated CRCs showed a tendency to preserved nuclear 
immunoreaction for Cyclin T2. The difference was statistically significant in the training 
set (p=0.004) but failed to reach significant level in the validation set (p=0.21) (see table 
2 in study IV). The expression of MTA1 and MBD4 did not show correlation between 
cancer types.  
 
 
 
4.2 EPHB2 mutation screening and promoter hypermethylation analysis 
 
Altogether 24 serrated tumors were sequenced for somatic mutations in EPHB2. After 
sequencing 98% of the coding region no somatic mutations were detected. LOH was 
assessed using intronic SNPs. Three out of 12 (25%) informative samples showed LOH 
at EPHB2 locus. Promoter was hypermethylated in 5 out of 8 (63%) tumors.   
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DISCUSSION 
 
 
1. MSI AS A DIAGNOSTIC TOOL (I) 
 
The characteristic feature of Lynch syndrome is an early onset CRC. Affected patients 
often develop tumors before the reach the age of 50, and they often have synchronous and 
metachronous tumors. Many Lynch syndrome associated CRCs have been prevented 
because of an accurate diagnosis, regular colonoscopies and removal of early lesions. 
Järvinen et al., (2000) reported that the risk for CRC decreases by 50-60% if a 
colonoscopy is performed every three years. It is, therefore, very important to identify 
Lynch syndrome tumors, so that patients and their families can be directed to counseling 
and screening procedures.    
 
MSI is a practical tool in Lynch syndrome diagnostics. Up to 90% of Lynch syndrome 
tumors display MSI (Aaltonen et al., 1994; Pedroni et al., 1999). In 1997 the National 
Cancer Institute workshop on microsatellie instability suggested a panel of five 
microsatellite markers (BAT25, BAT26, D2S123, D5S346, D17S250), referred to as the 
Bethesda panel, to be used in MSI analysis (Boland et al., 1998). Back then there was 
little experience how practical the panel would be in everyday diagnostics. 
Quasimonomorphic mononucleotide markers, like BAT26, have some advantages when 
compared to dinucleotide markers. Allelic variations in the Caucasian population are rare 
(Samowitz et al., 1999), which obviates the use of the corresponding normal tissue in 
MSI analysis. In addition, interpretation of MSI from mononucleotide graphs is usually 
unequivocal.    
 
In study I we examined the ability of BAT26 to identify tumors harboring germline 
MMR gene mutations compared to the whole set of Bethesda markers. Out of 494 
samples included in this study 73 had previously been designated as MSI when analyzed 
with BAT26 alone, 27 samples had a germline MMR gene mutation. BAT26 detected all 
mutation positive samples, and 97% (93/95) of all MSI-H cases. The two novel MSI-H 
cases arising after analysis with the Bethesda panel did not harbor a mutation in MLH1, 
MSH2 or MSH6 genes, and showed instability only with dinucleotide markers. BAT26, 
thus, appears to be a sensitive marker when prescreening putative Lynch syndrome 
patients. 
 
It has been suggested that the Bethesda set would underestimate the number of MSI-H 
tumors and overestimate the number of MSI-L tumors because the panel consists of two 
mononucleotide markers and three dinucleotide markers. Adding more mononucleotide 
markers would improve the sensitivity of the panel (Umar et al., 2004). Suraweera et al. 
(2002) has shown that a set of five quasimonomorphic mononucleotide markers evaluates 
tumor MSI status accurately. All five markers can be pooled and amplified in a single 
PCR reaction, it is, therefore, simpler to use than the Bethesda panel and is more specific 
than using BAT26 alone. Using an extended set of mononucleotide markers may be 
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arguable. Although BAT26 is sensitive in detecting MSI, and in our study it identified all 
mutation positive cases, it has also failed to detect mutation positive cases (Shia et al., 
2005). BAT26 is quasimonomorphic in Caucasian populations, but 12.6% of African 
Americans show allelic variation in BAT26 locus (Pyatt et al., 1999; Samowitz et al., 
1999b), therefore using BAT26 only in more mixed populations may lead to false 
positive samples. The use of BAT26 only may also become a problem in MSH2 deletion 
carriers as BAT26 is located in MSH2. 
 
Using dinucleotide markers in diagnostic purposes has been shown to be fairly 
impractical. Dinucleotide markers are often polymorphic, thus their use in MSI analysis 
requires the analysis of the respective normal DNA. This is often laborious and time 
consuming. Moreover, interpretation of MSI in dinucleotide repeats can be difficult 
which leads to misclassifications. The role of MSI-L in tumors is not clear. It has been 
suggested that only MSI-H characterizes tumors with true MMR defect (Laiho et al., 
2002; Tomlinson et al., 2002). The National Cancer Institute workshop suggested in 2004 
that MSI-L classification for clinical purposes should be reconsidered. In our study the 
two novel MSI-H cases showed instability only with two dinucleotide markers in the 
absence of BAT26 instability. Both samples expressed MLH1, MSH2, and MSH6, and 
no germline mutation in MMR genes were detected.  
 
As a diagnostic tool MSI alone is not sufficient. It is specific but not very sensitive since 
approximately 15% of unselected CRCs display MSI as well, and only a subset is Lynch 
syndrome cases. Potential Lynch syndrome tumors are selected to MSI analysis based on 
evaluation of the family history. Positive MSI test indicates a possible gene defect but it 
does not pinpoint the actual mutated gene. Immunohistochemical staining of MMR genes 
is often used to identify the underlying gene, and the mutation is confirmed by direct 
sequencing. Since the first recommendations of the National Cancer Institute workshop in 
1998, several research groups have studied whether MSI analysis can be replaced using 
immunohistochemistry alone. It appears that immunohistochemistry does not quite reach 
the sensitivity of MSI analysis. Since it fails to detect some mutation positive cases, 
immunohistochemistry alone is not a sufficient tool either (Lindor et al., 2002; Chapusot 
et al., 2004; Halvarsson et al., 2004; Jover et al., 2004; Muller et al., 2004; Shia et al., 
2005). However, MSI analysis together with immunohistochemistry appears to be highly 
sensitive and reliable method to identify Lynch syndrome patients. 
 
 
2. THE ROLE OF MSI-L IN COLORECTAL TUMORS (II) 
 
Classifying colorectal tumors according to MSI status has clear impact on patient 
diagnosis and treatment. MSI-H tumors are molecularly and clinically different from both 
MSS and MSI-L tumors; one of the most significant differences being a more favorable 
prognosis (Gryfe et al., 2000; Ward et al., 2001). Prognosis, besides that it is of pivotal 
importance for patients, it also guides the nature and intensity of treatment, such as 
chemotherapy. The National Cancer Institute workshop in 1998 suggested that CRCs 
should be divided into three subgroups, MSI-H, MSI-L, and MSS depending on the 
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proportion of markers that show MSI (Boland et al., 1998). The role of MSI-L tumors 
have been ambiguous, since they in many ways resemble MSS tumors (Lothe et al., 
1993; Cawkwell et al., 1997; Gonzalez-Garcia et al., 2000; Ward et al., 2001). While 
some studies have found molecular differences between MSI-L and MSS tumors, others 
have failed to distinguish the two groups. The aim in the study II was to examine if MSI-
L tumors truly form a relevant CRC subgroup, and to study whether the division of CRCs 
into three subgroups for clinical purposes is necessary. We also wanted to establish a cut-
off level for MSI-L, above which the tumors would display molecular and/or clinical 
features different from the tumors under the cut-off level. 
 
The markers selected in the Bethesda panel have been proposed to be sensitive in 
detecting MSI (Dietmaier et al., 1997; Boland et al., 1998). However, in our study they 
appeared to be quite insensitive. Thirteen markers listed in the Bethesda panel identified 
9 MSI-L tumors, thus leaving 62 tumors displaying similar degree of MSI undetected. It 
appears that the marker set used in MSI-L analysis so far is inadequate, since it only 
identifies a subset of MSI-L tumors. After completion of MSI analysis with 377 markers 
almost 80% of the tumors had displayed MSI. It is therefore conceivable to hypothesize 
that if even more markers would have been analyzed, all tumors would have scored as 
MSI-L. Jass et al., (2002) question the value of employing a large number of relatively 
stable markers, and suggest that only the markers that have proven to be sensitive in MSI-
L analysis should be applied. However, the 11 recommended Bethesda dinucleotide 
markers were in no way more sensitive than other dinucleotide markers in the set. The 
MSI sensitivity of the 11 most sensitive markers in our set of 364 randomly chosen 
dinucleotide markers was equal or better than the most sensitive Bethesda marker 
D2S123. If the MSI-L analysis of this tumor set would have been performed first using 
the 11 markers listed in the Bethesda panel, and subsequently using the 11 markers that 
were the most sensitive among the 364 randomly chosen dinucleotide markers, the two 
sets of detected MSI-L tumors would have been almost completely different (see Figure 1 
in study IIb).        
      
The reported differences between MSI-L and MSS tumors include higher KRAS mutation 
frequency, apoptotic activity, and lymphocytic infiltration, lower LOH frequency in 
chromosome 5q, and reduced Bcl-2 expression in MSI-L tumors (Biden et al., 1999; Jass 
et al., 1999; Michael-Robinson et al., 2001). It has also been reported that MGMT gene 
promoter methylation correlates with KRAS mutations in MSI-L tumors (Whitehall et al., 
2001). In the study II we analyzed KRAS mutation frequency, promoter hypermethylation 
of MGMT and MLH1, LOH frequency at APC, p53, and SMAD4 loci, as well as several 
clinical features e.g. sex, stage, grade, site, and family history of cancer. The tumors 
displayed MSI at 0-11 loci. When examining all the possible cut-off levels for MSI-L we 
did not detect any convincing differences between the putative MSS and MSI-L tumors 
in terms of the above mentioned features (see Table 1 in study IIa). The distribution of 
microsatellite mutations was not, however, random, since tumors from older patients 
tended to have more mutations. Mutation rates observed in this data set are similar to the 
median rate of mutations observed in normal human fibroblasts (1.3x10-7 mutations per 
division) (Boyer and Farber, 1998), suggesting that the mutations detected in samples 
reflect the number of cell division and stochastic mutation (see Figure 3 in study IIa). Nor 
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did tumors show genetic heterogeneity in the microsatellite mutation patterns, suggesting 
that the mutations have occurred before the final clonal expansion. The study by Halford 
et al. (2002) also attempted to define the role of MSI-L. The study yielded highly similar 
results to ours; no differences between MSI-L and MSS tumors were observed, yet the 
distribution of microsatellite mutations was not random. Unfortunately Halford et al. 
(2002) did not proportion the number of mutations to patients’ age. Thus, it is not known 
if older patients displayed more microsatellite mutations in that data set as well. Halford 
et al. (2002) hypothesized that the difference in mutation frequency could be due to 
variation in the natural history of tumors. If a tumor had developed through a pathway 
that involved few cell divisions, fewer microsatellite mutations would have taken place. 
Another explanation could be polymorphisms in DNA repair genes that have only subtle 
affect on MMR system. 
 
 
 
 
 
    
 
Figure 6. D1S413 shows an example of a minor extra band, which failed to qualify as 
MSI. D2S151 illustrates an example where the RER-score was calculated to confirm the 
MSI status (RER-score 25%).   
 
 
PCR artefacts may also complicate MSI scoring. This could have hampered the 
assessment of MSI in many studies. Many of the DNA polymerases routinely used in 
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PCR reactions do not have a proofreading activity, and gains and losses of repetitive units 
occur also during PCR reaction. So-called stutter bands are frequently observed in 
sequencer outputs. In dinucleotide repeats losses of repeat units are much more frequent, 
but also gains are detected (Hite et al., 1996). Distinguishing PCR artifacts from real 
insertions in the cases which show small insertion bands is particularly difficult (Figure 
6). The mathematical model known as a RER-score can be utilized in determining the 
MSI status of visually ambiguous samples (Canzian et al., 1996). However, the RER-
score appear not to be widely applied, and in many studies only visual criteria are used in 
scoring MSI. 
 
In conclusion, it appears that MSS and MSI-L tumors have a common molecular 
background, and that distribution of CRCs into three subgroups does not seem to be 
justified at least for clinical purposes.  The mechanisms underlying colorectal cancer are, 
however, not clear, and further studies may prove the existence of a true MSI-L pathway. 
Therefore maintenance of MSI-L subgroup for research purposes may be entitled, but the 
current method to detect MSI-L tumors should be revised. 
 
 
3. CHARACTERIZATION OF CHROMOSOMAL REGIONS 
CONTAINING PUTATIVE LOW-RISK ALLELES FOR CRC (III) 
 
Much of our information about the molecular pathogenesis of cancer has arisen from 
studies on hereditary tumors. Dominantly inherited CRC syndromes account for 
approximately 5% of all CRCs (Mecklin, 1987; Aaltonen et al., 1998). The underlying 
gene defects causing CRC syndromes are well characterized. Besides that these genes are 
key players in the respective syndromes they also have a major role in sporadic colon 
tumorigenesis, exemplified by APC and SMAD4. Except the hereditary syndromes, the 
distinction between sporadic and familial CRCs is not unequivocal. The proportion of 
familial cases is often estimated to be 20-25%, however, it may be that up to 35% of 
CRCs can be ascribed to inherited genetic susceptibility (Lichtenstein et al., 2000). As is 
the case in hereditary syndromes, the moderate and low-penetrance alleles are likely to 
play an important role in sporadic tumorigenesis as well, and therefore cause a major 
burden to public health. Several such alleles involved in CRC predisposition have been 
identified (Table 7). 
 
The high penetrance genes predisposing to CRC have been identified through linkage 
analysis, but when the penetrance of an allele is low, the locus is difficult to identify by 
linkage, because the slightly increased risk that a low-penetrance gene confers may not be 
sufficient to generate significant familial clustering. Additionally, many of the unaffected 
family members carry the disease allele, which confuses calculations. Thus, alternative 
methods to identify predisposing loci must be applied. We compared AI frequency in 
familial tumors to their sporadic counterparts, and identified several chromosomal 
regions that displayed higher frequency of AI in the familial group. The most promising 
regions after genotyping all the three sample sets were located in chromosome 20: 
20p12.2 defined by D20S186, and 20q13.1-q13.3 defined by D20S178 and D20S171. 
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Table 7. Low-penetrance alleles predisposing to CRC (Laken et al., 1997; Houlston and 
Tomlinson, 2001; Gruber et al., 2002; Shaheen et al., 2003; Pashe et al., 2004)  
Gene Allele Population frequency Relative risk 
of CRC 
TGFβR1 6Ala (Polyalanine polymorphism) Caucasian, 14%  1.2 
APC I1307K Ashkenazi Jews, 5-7% 1.5-2.2 
HRAS1 variable number of tandem repeats 
(VNTR) 
Caucasian, 1-6% 2.5 
BLM 2281 delATCTGA insTAGATTC Ashkenazi Jews, 1%  2.4 
HFE H63D, C282Y USA, North Carolina, 
9%, 4%, respectively 
1.4 
 
 
Comparative genomic hybridization showed that the mechanism creating AI was 
amplification. Despite that most cancer susceptibility genes act as tumor suppressor or 
caretaker genes, oncogenic predisposition can occur as well. In hereditary papillary renal 
cell cancer the mutated MET proto-oncogene is amplified in tumors (Fischer et al., 1998). 
In 2003 Ewart-Toland et al., proposed the role of AURKA/(STK15) as a low-penetrance 
CRC susceptibility gene. AURKA is located in chromosome 20q13. It is a member of 
Aurora/Ipl1p family of serine-threonine kinases which are important regulators of 
chromosome segregation (Bischoff and Plowman, 1999). Misregulation of this process 
results in aneuploidy, a characteristic feature of many cancers. Ewart-Toland et al. (2003) 
showed that an A91 (Ile31) allele of AURKA was preferentially amplified in their set of 
162 colorectal tumors. Furthermore, they showed that tumors from individuals with even 
one copy of the AURKA A91 allele show a higher degree of aneuploidy than tumors from 
T91 homozygotes, and that in cultured cells an A allele induced more rapid cell growth. 
Besides CRC, the role of Ile31 of AURKA as a low-penetrance gene has since been 
proposed in breast, ovarian, and stomach cancer (Dicioccio et al., 2004; Miao et al., 2004; 
Sun et al., 2004). In the allelotyping study, no differences in 20q amplification were 
observed between familial and sporadic CRCs using quantitative PCR. The difference 
was, however, clear using microsatellites. Quantitative PCR can not separate between the 
two alleles, whereas microsatellite markers examine the status of alleles independently. 
This suggests that allele-specific amplification underlies the AI difference between 
familial and sporadic tumors.  
 
Allele-specific amplification of AURKA A91 has since been evaluated in 125 familial and 
110 sporadic CRCs from our sample collection. Consistent with the study by Ewart-
Toland et al. (2003), a preferential amplification of A91 allele was observed, and the 
allele specific amplification difference was more pronounced in the familial group 
(Hienonen et al., 2005). The preferential amplification of an A91 allele in the familial 
group suggests that the variant could confer a higher risk for CRC. Further studies are, 
however, needed to confirm the role of AURKA in colorectal tumor predisposition.  
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4. THE GENE EXPRESSION PROFILE OF THE SERRATED 
COLORECTAL TUMORS (IV) 
 
Two pathways that lead to CRC are well-established: MSS cancers evolve through the 
suppressor pathway and MSI cancers through the mutator pathway. Tumors arising 
through different pathways display mutations in different genes; APC, KRAS, and TP53 
are frequently mutated in MSS tumors, while MSI tumors have mutations in TGFβRII 
and BRAF. However, tumors that do not follow either of these pathways exist. Tumors 
arising through a serrated pathway may represent a new entity among CRCs. Serrated 
lesions combine the architectural features of hyperplastic polyps and the cytological 
features of conventional adenocarcinomas. Thus, they look morphologically different, but 
whether they are biologically different as well has not been clear. 
 
Previous studies have tried to tie together MSI and the serrated pathway, suggesting that 
serrated polyps give rise to MSI tumors (Iino et al., 1999; Jass et al., 1999; Jass et al., 
2000; Hawkins and Ward, 2001). On the contrary, in two recent studies serrated lesions 
have very rarely displayed MSI (Sawyer et al., 2002; Dong et al., 2005). Inconsistent 
results suggest that serrated CRCs form a heterogenous group of lesions and that among 
serrated tumors there are lesions that follow either the suppressor or the mutator pathway. 
In our dataset out of 45 serrated tumors 4 (8.9%) were MSI. Though it has fairly recently 
been proposed that serrated pathway exists, it has already been shown that serrated 
lesions have molecular features that distinguish them from conventional CRCs (Rashid et 
al., 2000; Sawyer et al., 2002; Kambara et al., 2004; Dong et al., 2005). The studies have, 
however, concentrated on few molecular features at a time; extensive genome-wide 
studies have not been performed so far.       
  
The difference between serrated and conventional adenocarcinomas was clearly present 
already in the unsupervised clustering. All the serrated samples, except for one, clustered 
together in the same branch (see Figure 1 in the study IV). Altogether 201 genes and 7 
ESTs were differentially expressed between the two groups. Using the predictor 
consisting of 27 probes it was possible to predict an unknown sample with 100% 
accuracy (see Supplementary table 5 in the study IV). Since these probes were repeatedly 
present in cross-validations, it is likely that at least some of them play a role in serrated 
tumorigenesis. 
  
The array results were validated by immunohistochemical staining of six differentially 
expressed genes: EPHB2, PTCH, HIF1α, CCNT2, MTA1, and MBD4. Staining of 
EphB2, Patched, and HIF1α showed a statistically significant association with tumor 
morphology. EphB2 is a receptor tyrosine kinase which has been shown to be critical for 
the right patterning of intestinal crypt-villus axis (Batlle et al., 2002). In prostate cancer 
EPHB2 acts as a tumor suppressor gene (Huusko et al., 2004). Due to its decreased 
expression in serrated samples we sequenced 24 serrated tumors for mutations in EPHB2, 
but found no somatic mutations. In 63% (5/8) of serrated tumors EPHB2 promoter was 
hypermethylated, and 25% (3/12) displayed LOH at EPHB2 locus. It appears that EPHB2 
is silenced by LOH and methylation.  Progressive methylation has been observed in 
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serrated lesions (Dong et al., 2005). Similarly, loss of chromosome 1p is observed 
already in hyperplastic polyps (Rashid et al., 2000).  
 
Patched (Ptch) is a receptor in the Hedgehog (HH) signaling pathway. Correct HH 
signaling is crucial during development of gastrointestinal tract, as well as in maintaining 
stem cells (Oldak et al., 2001). In the absence of the HH signal Ptch represses 
Smoothened (Smo). Binding of a HH protein to Ptch releases the repression of Smo 
which transmits the HH signal through Gli proteins. Inactivation of Ptch is equivalent to 
constant HH signaling. Patients affected with Gorlin syndrome have a germline mutation 
in PTCH. The syndrome is characterized by early onset multiple basal cell carcinomas 
and higher rate of other tumors e.g. medulloblastomas (Hahn et al., 1996; Johnson et al., 
1996). Loss of PTCH have been reported in sporadic forms of the same tumor types 
(Taipale and Bleachy, 2001), but not in primary CRCs. Disruption of the HH signaling 
pathway in serrated tumors may represent a novel route to CRC.  
 
HIF1α is expressed in lack of oxygen. HIF1α is a transcription factor which is able to 
induce transcription of genes needed in hypoxia (Ratcliffe et al., 1998). Some tumors 
displayed focal HIF1α positivity, while others showed diffuse positivity throughout the 
tumor. HIF1α expression was higher in serrated tumors, and serrated tumors displayed 
more often diffuse staining pattern in immunohistochemistry.   
 
Cyclin T2 showed statistically significant difference in the expression pattern in the 
training set which confirms the expression difference for the respective samples on array. 
The result did not reach statistically significant level in the validation set, thus lower 
expression of Cyclin T2 can not be generalized as a marker for serrated tumors. Cyclins 
are proteins that act together with cyclin-dependent kinases (CDKs) in the cell cycle 
regulation. Cyclin T2 is able to phosphorylate RNA polymerase II, and regulate 
transcriptional elongation of RNA by forming a complex with CDK9 (De Luca et al., 
2002).  
 
Both MTA1 and MBD4 showed significant expression difference in arrays. Despite that 
neither of the genes showed correlation between cancer types in immunohistochemistry. 
However, changes in RNA level do not necessarily reflect changes in protein level. It is 
also possible that the change in the protein level is too small to be detected in 
immunohistochemistry. In all, the results of the immunohistochemistry support the array 
results. 
 
This study shows that serrated CRCs differ from conventional CRCs not only 
morphologically but at the molecular level as well. This work has brought out some 
potential candidates playing a role in serrated tumorigenesis and further studies should 
establish the mechanisms and key molecules underlying serrated CRCs.   
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SUMMARY AND CONCLUSIONS 
 
 
In the current study several molecular methods to classify colorectal cancer were studied.  
The practicality of the Bethesda microsatellite marker panel in hereditary CRC 
diagnostics was compared to mononucleotide marker BAT26, the role and extent of low-
level MSI was analyzed, new chromosomal regions containing putative low-
predisposition alleles were localized, and molecular differences between serrated and 
conventional CRCs were studied. From the results of the study the following conclusions 
were made: 
 
 
1. BAT26 was found to be a sensitive tool in Lynch syndrome diagnostics. It 
identified all mutation positive samples in the dataset, but failed to identify two 
MSI-H and 20 MSI-L samples. These samples did not display known MMR 
defects. Analysis of additional four markers added workload and costs, and 
increased difficulties in MSI scoring but did not increase sensitivity. BAT26 alone 
can be used in Lynch syndrome diagnostics especially if resources are limited. 
 
2. When a large number of microsatellites are studied, most CRCs display low-level 
MSI. The commonly used 5-15 markers are inadequate to define MSI-L tumors, 
since they fail to detect majority of lesions displaying similar degree of MSI-L. 
Neither clinical nor molecular differences were observed between MSI-L and 
MSS CRCs. However, the distribution of microsatellite mutations was not 
random; older patients tended to have more mutations. MSI-L and MSS tumors 
appear to have a common molecular background, and the observed instability 
difference reflects number of cell divisions and stochastic mutation. 
 
3. Allelotyping of familial and sporadic CRCs revealed several chromosomal 
regions that potentially harbor novel CRC predisposition genes. The most 
promising region was located on chromosome 20q where familial tumors showed 
more AI compared to sporadic ones. The mechanism creating AI was shown to be 
amplification. Genome-wide AI analysis provides an alternative strategy to 
identify cancer predisposition genes, since it obviates the requirement to collect 
multiple samples from families. 
 
4. Serrated CRCs differed from conventional CRCs on gene expression level and 
formed a distinct branch in the hierarchical clustering tree. Several differentially 
expressed genes were identified, and the differences were shown at protein level 
as well. The study supports the existence of serrated neoplasia pathway, and 
shows that serrated tumors are different from conventional CRCs not only 
morphologically but also molecularly.   
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